US20140341802A1 - Provasopressin antagonists and uses thereof - Google Patents

Provasopressin antagonists and uses thereof Download PDF

Info

Publication number
US20140341802A1
US20140341802A1 US14/274,997 US201414274997A US2014341802A1 US 20140341802 A1 US20140341802 A1 US 20140341802A1 US 201414274997 A US201414274997 A US 201414274997A US 2014341802 A1 US2014341802 A1 US 2014341802A1
Authority
US
United States
Prior art keywords
provasopressin
cancer
antibody
mag
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/274,997
Other languages
English (en)
Inventor
William G. North
Roy H.L. Pang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Woomera Therapeutics Inc
Original Assignee
Woomera Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Woomera Therapeutics Inc filed Critical Woomera Therapeutics Inc
Priority to US14/274,997 priority Critical patent/US20140341802A1/en
Publication of US20140341802A1 publication Critical patent/US20140341802A1/en
Priority to US15/289,260 priority patent/US10155810B2/en
Priority to US16/575,911 priority patent/US20220242947A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A61K47/48553—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6847—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a hormone or a hormone-releasing or -inhibiting factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1024—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against hormones, hormone-releasing or hormone-inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C07K2316/96—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Definitions

  • Ovarian cancer is the fifth leading causes of death from cancer among women throughout the world, and accounts for the death of approximately 16,000 women in the United States each year (Young, “Gynecologic Malignancies,” in J. N. Jameson, D. L. Kasper, T. R. Harrison, E. Braunwald, A. S. Fauci, S. L. Hauser, D. L. Longo (eds.) Harrison's Principles of Internal Medicine, 16th Edition, McGraw-Hill, New York, N.Y., 2005). Although there have been many recent advances for effectively treating this disease (Goff et al., “Ovarian carcinoma diagnosis,” Cancer 89: 2068-2075, 2000; Chobanian and Dietrich, “Ovarian Cancer,” Surg. Clin.
  • Pancreatic cancer is the eighth most frequent type of solid tumor arising worldwide, but, as a consequence of the current lack of effective therapy, it is the fourth most frequent cause of cancer death (Gunzburg and Salmons, Trends Mol. Med. 7(1):30-37, 2001). It is estimated that 29,200 cases will be diagnosed in the United States in 2001, and 28,900 of these patients are expected to die ( Cancer Facts and Figures, 2001. Atlanta, Ga., American Cancer Society, 2001).
  • cancer of the prostate is a serious health problem in terms of drawn-out personal suffering and premature death not to mention the cost to the health care system.
  • the incidence of prostate cancer appears to be increasing, over and above improved detection rates in recent years (Post et al., 1999). Although many men with cancer of the prostate die from other causes, the high incidence results in significant morbidity and death directly from the prostatic tumor.
  • Currently-available therapy carries a significant risk of major side effects, including incontinence and impotence, and consequently many men are reluctant to accept treatment at an early stage of the disease.
  • the need to improve the treatment of prostate cancer is underlined by the existence of over 150 clinical trials world wide ( Future Oncology , vol. 4, number 3, 1998).
  • vasopressin The expression of the vasopressin gene is largely restricted to hypothalamic neurons, and it encodes for a protein product of ⁇ 17 kDa, to which an N-glycosidic side-chain of ⁇ 4 kDa is added, resulting in the ⁇ 20 kDa provasopressin (pro-VP) precursor.
  • This protein is normally packaged into secretory vesicles where it undergoes enzymatic cleavage to generate vasopressin (VP), VP-associated neurophysin (VP-NP), and VP-associated glycopeptide (VAG) (North, W. G. In: D. Gash and G. Boer (eds.), Vasopressin: Principles and Properties , pp.
  • SCLC tumors and cultured cells also express the VP gene, however intact provasopressin protein can become localized to the cell surface plasma membrane (Friedmann et al., B. J. Cancer 69: 260-263, 1994; North et al., Ann. NY Acad. Sci. 689: 107-121, 1993).
  • Polyclonal antibodies raised against VP-NP bind specifically to the surface of cultured SCLC cells, as determined by immunofluorescent analysis (Friedmann et al., Neuropeptides 28: 183-189, 1995; North et al., Prog. Brain Res.
  • NRSA neurophysin-related cell surface antigen
  • Polyclonal anti-VP-NP antibodies recognize proteins of ⁇ 20 kDa and ⁇ 40 kDa in total protein extracts from SCLC cultured cells by Western analysis (North et al., Peptides 14: 303-307, 1993).
  • the ⁇ 20 kDa protein corresponds in size to the provasopressin protein, and the ⁇ 40 kDa protein is believed to be a related form (Camier et al., FEBS Lett., 108: 369-373, 1979; Lauber et al., FEBS Lett., 97: 343-347, 1979; Lauber et al., Proc. Natl. Acad. Sci. USA, 78: 6086-6090, 1981; Moore and Rosenior, Prog. Brain Res. 60: 253-256, 1983; Nicolas et al., Proc. Natl. Acad. Sci.
  • VP vasopressin
  • DCIS breast cancer/ductal carcinoma in situ
  • GRSA Glycopeptide-Related cell Surface Antigen
  • antagonists e.g., antibodies and antigen-binding portions thereof
  • methods of using compositions comprising such antagonists for example, to image cancer cells in vivo and in biological samples. Said compositions may also be used for treating patients suffering from a provasopressin-expressing cancer.
  • Provasopressin-expressing cancers include (but are not limited to) neuroendocrine cancer, pancreatic cancer, and prostate cancer.
  • the invention is based in part on the realization that the subject antagonists, e.g., antibodies or antigen-binding portions thereof, which bind provasopressin, are useful as therapeutic agents and/or diagnostic agents for provasopressin-expressing cancers, including certain pancreatic cancers, prostate cancers, and neuroendocrine cancers that express provasopressin.
  • the subject antagonists e.g., antibodies or antigen-binding portions thereof, which bind provasopressin
  • the invention provides a method of treating a provasopressin (pro-VP)-expressing cancer, comprising administering a therapeutically effective amount of a provasopressin-binding antagonist (e.g., an antibody or antigen-binding portion thereof) to a patient in need thereof.
  • a provasopressin-binding antagonist e.g., an antibody or antigen-binding portion thereof
  • the provasopressin-expressing cancer is not small cell lung cancer (SCLC) or breast cancer.
  • SCLC small cell lung cancer
  • the cancer is a neuroendocrine, prostate, or pancreatic cancer.
  • the neuroendocrine cancer is a brain, gastroenteric, ovarian, endomedrial, testicular, adrenal, or skin cancer.
  • the invention provides a method of treating a provasopressin-expressing (pro-VP-expressing) cancer, comprising administering, to a patient in need thereof, a therapeutically effective amount of a provasopressin-binding agent (such as an anti-provasopressin antibody or antigen-binding portion thereof, preferably MAG-1, MAG-2, MAG-3, MAG-4, MAG-5, or other antibodies similarly raised and having similar binding specificity/affinity), and a therapeutically effective amount of a pharmaceutical composition comprising a chemotherapeutic agent (such as cyclophosphamide or similar chemotherapeutic agents).
  • a provasopressin-expressing (pro-VP-expressing) cancer comprising administering, to a patient in need thereof, a therapeutically effective amount of a provasopressin-binding agent (such as an anti-provasopressin antibody or antigen-binding portion thereof, preferably MAG-1, MAG-2, MAG-3, MAG-4, MAG-5, or other antibodies similarly
  • the provasopressin-binding antibody binds to the VAG region of the pro-VP protein. In certain embodiments, the provasopressin-binding antibody binds to the linker region of the pro-VP protein. In certain embodiments, the provasopressin-binding antibody binds to the VP-NP region of the pro-VP protein.
  • the provasopressin-binding antibody is a mouse antibody, a human antibody, a mouse-human chimeric antibody, a humanized antibody.
  • the antigen-binding portion thereof is scFv, Fab, F(ab′) 2 , Fd, Fv, or dAb.
  • the provasopressin-binding antibody is MAG-1, MAG-2, MAG-3, MAG-4, or MAG-5, or antibodies having similar binding specifity, including human antibody, humanized antibody, or chimeric antibody thereof.
  • the antibody may be a human antibody thereof, preferably having substantially the same or higher binding affinity; or a humanized antibody thereof, preferably having substantially the same or higher binding affinity); or a chimeric antibody thereof, preferably having substantially the same or higher binding affinity.
  • the antibody or antigen-binding portion thereof does not elicit a strong immune response from a patient.
  • the antibody or antigen-binding portion thereof may have few or no epitopes recognized by human T cell receptors.
  • the methods herein may further comprise administering an effective amount of a pharmaceutical composition comprising a chemotherapeutic agent.
  • This pharmaceutical composition comprising a chemotherapeutic agent may further comprise epinephrine.
  • the pharmaceutical compositions are administered concomitantly.
  • the pharmaceutical compositions are administered in a single formulation. Alternatively, the pharmaceutical compositions may be administered as separate formulations.
  • one may further administer an effective amount of a pharmaceutical composition comprising at least one of dexamethasone, IBMX, 8-bromoadenosine 3′,5′-cyclic monophosphate (8br-cAMP), cyclophosphamide, cisplatin, etoposide VP-16 and forskolin.
  • a pharmaceutical composition comprising at least one of dexamethasone, IBMX, 8-bromoadenosine 3′,5′-cyclic monophosphate (8br-cAMP), cyclophosphamide, cisplatin, etoposide VP-16 and forskolin.
  • the methods herein comprise performing surgical removal of at least one tumor from the patient.
  • the methods may also comprise performing radiation therapy.
  • the methods may further comprise administering a somatostatin analogue (e.g., those resistant to proteolytic enzymes and having longer half-lives, including Octreotide (SMS 201-995, Sandostatin), Somatuline (BIM 23014), Lanreotide, and RC 160 (Octastatin, Vapreotide), see de Herder et al., Postgrad. Med. J.
  • a somatostatin analogue e.g., those resistant to proteolytic enzymes and having longer half-lives, including Octreotide (SMS 201-995, Sandostatin), Somatuline (BIM 23014), Lanreotide, and RC 160 (Octastatin, Vapreotide), see de Herder et al., Postgrad. Med. J.
  • the antagonist may further comprise a label.
  • the label is selected from the group consisting of a fluorescent label, a radiolabel, a toxin, a metal compound, and biotin.
  • the fluorescent label is selected from the group consisting of Texas Red, phycoerythrin (PE), cytochrome c, and fluorescent isothiocyanate (FITC).
  • the fluorescent label comprises a fluorescent protein or a protein that binds a fluorescent label. Examples of fluorescent proteins include dsRed, mRFP, YFP, GFP, CFP, BFP, and Venus.
  • the radiolabel is selected from the group consisting of 32 P, 33 P, 43 K, 47 Sc, 52 Fe, 57 Co, 64 CU, 67 Ga, 67 Cu, 68 Ga, 71 Ge, 75 Br, 76 Br, 77 Br, 77 As, 77 Br, 81 Rb/ 81M Kr, 87M Sr, 90 Y, 97 Ru, 99 Tc, 100 Pd, 101 Rh, 103 Pb, 105 Rh, 109 Pd, 111 Ag, 111 In, 113 In, 119 Sb 121 Sn, 123 I, 125 I, 127 Cs, 128 Ba, 129 Cs, 131 I, 131 Cs, 143 Pr, 153 Sm, 161 Tb, 166 Ho, 169 Eu, 177 Lu, 186 Re, 188 Re, 189 Re, 191 Os, 193 Pt, 194 Ir, 197 Hg,
  • the toxin is selected from the group consisting of ricin, ricin A chain (ricin toxin), Pseudomonas exotoxin (PE), diphtheria toxin (DT), Clostridium perfringens phospholipase C (PLC), bovine pancreatic ribonuclease (BPR), pokeweed antiviral protein (PAP), abrin, abrin A chain (abrin toxin), cobra venom factor (CVF), gelonin (GEL), saporin (SAP), modeccin, viscumin and volkensin.
  • ricin ricin A chain
  • PE Pseudomonas exotoxin
  • DT diphtheria toxin
  • PLC Clostridium perfringens phospholipase C
  • BPR bovine pancreatic ribonuclease
  • PAP pokeweed antiviral protein
  • abrin abrin
  • abrin A chain
  • Another aspect of the invention provides a method of killing provasopressin-expressing cancer cells, comprising contacting the provasopressin-expressing cancer cells with a provasopressin-binding antagonist (e.g., an antibody or an antigen-binding portion thereof).
  • a provasopressin-binding antagonist e.g., an antibody or an antigen-binding portion thereof.
  • the provasopressin-expressing cancer cell is not a SCLC cell and not a breast cancer cell.
  • the invention provides a method of killing a provasopressin-expressing cancer cell, comprising contacting the provasopressin-expressing cancer cell with a provasopressin-binding agent (such as an anti-proVP antibody or an antigen-binding portion thereof, preferably MAG-1 or other related MAG antibodies), and a chemotherapeutic agent (such as cyclophosphamide).
  • a provasopressin-binding agent such as an anti-proVP antibody or an antigen-binding portion thereof, preferably MAG-1 or other related MAG antibodies
  • a chemotherapeutic agent such as cyclophosphamide
  • the provasopressin-expressing cancer cells are SCLC or breast cancer cells.
  • the invention provides a method of inhibiting the growth and/or proliferation of provasopressin-expressing cancer cells, comprising contacting the provasopressin-expressing cancer cells with a provasopressin-binding antagonist (e.g., an antibody or an antigen-binding portion thereof).
  • a provasopressin-binding antagonist e.g., an antibody or an antigen-binding portion thereof.
  • the provasopressin-expressing cancer cells are not SCLC or breast cancer cells.
  • the provasopressin is on the surface of the provasopressin-expressing cancer cells.
  • the invention provides a method of inhibiting the growth of a provasopressin-expressing cancer cell, comprising contacting the provasopressin-expressing cancer cell with a provasopressin-binding agent (such as an anti-pro-VP antibody or an antigen-binding portion thereof, preferably MAG-1 or other related MAG antibodies), and a chemotherapeutic agent (such as cyclophosphamide).
  • a provasopressin-binding agent such as an anti-pro-VP antibody or an antigen-binding portion thereof, preferably MAG-1 or other related MAG antibodies
  • a chemotherapeutic agent such as cyclophosphamide
  • the provasopressin-expressing cancer cells are SCLC or breast cancer cells.
  • Another aspect of the invention also provides a method of phenotyping biological samples from patients having a provasopressin-expressing cancer, other than breast cancer or small cell lung cancer, the method comprising: (a) obtaining a biological sample from a patient, optionally rendering the biological sample amenable to immunoassay; (b) contacting the sample with a provasopressin-binding antagonist (e.g., an antibody or antigen-binding portion thereof), under conditions that allow for binding of the antagonist to provasopressin; and (d) determining if the cells of the sample inappropriately express provasopressin compared to a control tissue; wherein if the test tissue inappropriately expresses provasopressin, the biological sample is identified as likely having cancerous cells.
  • a provasopressin-binding antagonist e.g., an antibody or antigen-binding portion thereof
  • Another related aspect of the invention provides a method of identifying a patient suitable for treatment with the subject binding agent specific for provasopressin, by diagnosing the presence in a patient a tumor/cancer expressing provasopressin, the method comprising: a) obtaining a biological sample (such as a biopsy) from the patient; b) if necessary, rendering the biological sample amenable to immunoassay; c) contacting the sample with an antibody or an antigen-binding portion thereof specific for provasopressin, under conditions that allow for binding of the antibody or antigen-binding portion to provasopressin; and d) determining if the cells of the sample expresses a significantly higher level of provasopressin compared to a control tissue; wherein the patient is selected for treatment with the subject binding agent specific for provasopres sin if the cells of the sample express a significantly higher level of provasopressin compared to the control tissue.
  • the method further comprises treating the identified/selected patient by administering to the patient one or more
  • a therapeutically effective amount of a provasopressin-binding antagonist e.g., antibody or antigen-binding portion thereof is administered to the patient.
  • the patient before step (a), the patient has been diagnosed as having a provasopressin-expressing cancer, such as prostate cancer, pancreatic cancer, or neuroendocrine cancer.
  • a provasopressin-expressing cancer such as prostate cancer, pancreatic cancer, or neuroendocrine cancer.
  • kits useful for screening a biological sample for a provasopressin-expressing cancer other than breast cancer or small cell lung cancer comprising a provasopressin-binding antagonist (e.g., antibody or antigen-binding portion thereof).
  • the kit may be labeled for use in detecting a provasopressin-expressing cancer such as prostate cancer, pancreatic cancer, or neuroendocrine cancer.
  • the kit may also include instructions stating that the kit is for use in diagnosing a provasopressin-expressing cancer such as prostate cancer, pancreatic cancer, or neuroendocrine cancer.
  • Another aspect of the invention provides a method of detecting a tumor in a patient having a provasopressin-expressing cancer other than breast cancer or small cell lung cancer, the method comprising: (a) administering a pharmaceutical composition comprising a provasopressin-binding antagonist (e.g., antibody or antigen-binding portion thereof) to the patient, (b) detecting the label, and (c) determining if the patient has cells that inappropriately express provasopressin compared to a control; wherein if the patient has cells that inappropriately express provasopressin, the patient is identified as likely having a tumor.
  • a provasopressin-binding antagonist e.g., antibody or antigen-binding portion thereof
  • Another related aspect of the invention provides a method of identifying a patient suitable for treatment with the subject binding agent specific for provasopressin, by detecting a tumor in a patient having a provasopressin-expressing cancer other than breast cancer or small cell lung cancer, the method comprising: (a) administering a pharmaceutical composition comprising a provasopressin-binding antagonist (e.g., antibody or antigen-binding portion thereof) to the patient, (b) detecting the label, and (c) determining if the patient has cells that inappropriately express provasopressin compared to a control; wherein if the patient has cells that inappropriately express provasopressin, the patient is identified as likely having a tumor and is identified as suitable for treatment with the subject binding agent specific for provasopressin.
  • a provasopressin-binding antagonist e.g., antibody or antigen-binding portion thereof
  • the method further comprises, if the patient has cells that inappropriately express provasopressin, administering a therapeutically effective amount of a provasopressin-binding antagonist (e.g., antibody or antigen-binding portion thereof) to the patient.
  • a provasopressin-binding antagonist e.g., antibody or antigen-binding portion thereof
  • step (a) the patient has been diagnosed as having a provasopressin-expressing cancer.
  • the method may further comprise determining the location and/or volume of a plurality cells inappropriately expressing provasopressin (for example, determining the volume of a tumor). This method may be used to determine the location of a tumor prior to surgical resection of the tumor. It may also be used to determine whether surgery is appropriate.
  • the cancer is not SCLC or breast cancer. In some embodiments, the cancer is not ductal carcinoma in situ (DCIS)—a type of breast cancer.
  • DCIS ductal carcinoma in situ
  • Provasopressin-binding antibodies may have, for example, at least 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% amino acid sequence identity to MAG-1, MAG-2, MAG-3, MAG-4, or MAG-5.
  • the antibodies may have variable regions that have at least 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% amino acid sequence identity to the variable regions of MAG-1, MAG-2, MAG-3, MAG-4, or MAG-5.
  • the antibody or antigen-binding portion thereof may comprise the complementary determining regions (CDR) of the antibody or antigen-binding portion of the disclosed antibodies, and human framework regions.
  • CDR complementary determining regions
  • Another aspect of the invention provides a method of treating a neuroendocrine cancer, comprising administering a therapeutically effective amount of a provasopressin-binding antibody or antigen-binding portion thereof to a patient in need thereof, wherein the cancer is not small cell lung cancer.
  • Another aspect of the invention provides a method of killing neuroendocrine cancer cells, comprising contacting the neuroendocrine cancer cells with a provasopressin-binding antibody or an antigen-binding portion thereof, wherein the neuroendocrine cancer cells are not small cell lung cancer cells.
  • Another aspect of the invention provides a method of inhibiting the growth of neuroendocrine cancer cells, comprising contacting the neuroendocrine cancer cells with a provasopressin-binding antibody or an antigen-binding portion thereof, wherein the neuroendocrine cancer cells are not small cell lung cancer cells.
  • the cancer cells express provasopressin.
  • anti-provasopressin antagonists e.g., antibodies and antigen-binding portions thereof
  • the antagonists may be used in tissue culture or in a model organism to study the mechanism by which anti-provasopressin antibodies inhibit cancer.
  • FIG. 1 illustrates detection of NRSA in cultured SCLC cells and human SCLC tissue by RT-PCR analysis.
  • RT-PCR was performed on total RNA extracts from the indicated cell lines or human tissue. Products were separated on a 1.5% agarose gel and visualized with ethidium bromide.
  • the PCR primers were designed to amplify the entire coding region for the pro-VP protein, which spans 2 introns. The predicted size for the amplification is 570 bp.
  • Lu-165 and NCI-H345; SCLC cell lines, Beas-2B; transformed normal human epithelial cell line, lung and hypothalamus; human tissue extracts were tested.
  • FIGS. 2A and 2B show detection of NRSA in cultured SCLC cells and human SCLC tissue by Western analysis.
  • FIG. 2A illustrates staining with MAG-1 mAb or MAG-1 Fab.
  • FIG. 2B illustrates staining with MAG-1 mAb or a rabbit polyclonal antibody against VP-NP. Approximate molecular mass is indicated on the left of each figure.
  • Total cellular or tissue protein extracts (40 ⁇ g) were separated by SDS-PAGE, blotted onto polyvinylidene difluoride (PDVF) membrane, and reacted with ( FIG. 2A ) MAG-1 mAb or MAG-1 Fab, and with ( FIG. 2B ) MAG-1 mAb or a rabbit polyclonal antibody against VP-NP.
  • PDVF polyvinylidene difluoride
  • FIGS. 3A through 3D show flow cytometry analysis of MAG-1 binding to the surface of cultured SCLC cells.
  • FIG. 3A illustrates MAG-1 Fab staining of NCI-H82 cells at two different concentrations compared to a control IgG1 antibody.
  • FIG. 3B illustrates MAG-1 mAb staining of NCI-H345 cells compared to a control IgG1 antibody.
  • FIG. 3C illustrates MAG-1 mAb staining of NCI-H82 cells at two different concentrations compared to a control IgG1 antibody.
  • FIG. 3D illustrates MAG-1 mAb staining of Lu165 cells compared to a control IgG1 antibody.
  • Antibody staining procedures prior to flow cytometry were performed using conditions that minimize plasma membrane internalization.
  • MAG-1 mAb and MAG-1 Fab were employed at a concentration of 100 ⁇ g/ml except where noted.
  • FIGS. 4A-4C show confocal analysis of MAG-1 binding to the surface of cultured SCLC cells.
  • SCLC cells were reacted with MAG-1 or an isotype control mAb, followed by FITC-labeled secondary antibodies.
  • FIG. 4A illustrates combined differential interference contrast (DIC) transmitted, red fluorescent, and green fluorescent light channel images of NCI-H82 cells viewed with a 40 ⁇ objective (NA 1.4) and a 5.8 ⁇ magnification zoom setting. The cells were incubated with propidium iodide to stain the nuclei (gray) for contrast.
  • DIC differential interference contrast
  • NCI-H345 illustrates imaged by confocal microscopy and the top panels display the control IgG1 observed with a 20 ⁇ objective (0.5 NA) and the lower panels display the MAG-1 stained cells observed with a 40 ⁇ objective (1.3 NA).
  • FIG. 4C illustrates Lu-165 cells imaged by confocal microscopy with a 40 ⁇ objective.
  • the left panels depict the transmitted light channel images
  • the middle panes depict the green fluorescent light channel images
  • the right panels depict the two combined images.
  • FIGS. 5A and 5B illustrate immunohistochemical analysis of human tissue sections using MAG-1 mAb.
  • FIG. 5A depicts MAG-1 immunoreactivity with human SCLC tumor cells (brown staining).
  • FIG. 5B depicts control normal epithelial cells of the alveoli of the lung.
  • FIG. 5C depicts control normal epithelial cells of the bronchioles of the lung.
  • FIGS. 6A and 6B illustrate the amino acid sequence and nucleic acid sequence of a single chain variable fragment immunoreactive with the C-terminal 18-amino acid residues of VAG.
  • FIG. 6A depicts the amino acid sequence (SEQ ID NO: 2).
  • FIG. 6B depicts the nucleic acid sequence (SEQ ID NO: 3).
  • FIG. 7 illustrates staining of human ductal carcinoma in situ (DCIS) tumor tissue sections examined by immunohistochemical analysis using MAG-1.
  • FIG. 8 shows representative immunohistochemistry (IHC) staining of three ovarian cancer sections (OC1, OC2, and OC3) with the mouse monoclonal antibody MAG-1.
  • FIG. 9 shows representative immunohistochemistry (IHC) staining of three prostate cancer sections (PC1, PC2, and PC3) with the mouse monoclonal antibody MAG-1.
  • FIG. 10 shows confocal images of A2780 and SK-OV3 ovarian cancer cells stained with fluorescent labeled MAG-1 antibody.
  • FIG. 11 shows confocal images of LNCAP lung cancer cells stained with fluorescent labeled MAG-1 antibody.
  • FIGS. 12A and 12B show that cMAG and MAG-1 inhibit MB231 breast cancer cell line growth ( FIG. 12A ), and that MAG-1 inhibits A2780 ovarian cancer cell line growth ( FIG. 12B ).
  • FIGS. 13A-13E show confocal images of cell surface localization of the GRSA antigen in SKOV3 cells ( FIG. 13A ), bxpc3 cells ( FIG. 13B ), prostate cancer cell line PC3 ( FIG. 13C ), OV2008 cells ( FIG. 13D ), and panc1 cells ( FIG. 13E ).
  • FIGS. 14A-14C show confocal microscopy images of SKBr3 cells incubated with ( FIG. 14A ) mouse antibody MAG-1, ( FIG. 14B ) chimeric antibody cMAG-1, and ( FIG. 14C ) humanized antibody hMAG-1.
  • FIGS. 15A and 15B show results of treating MCF-7 tumors ( 15 A) and MDA-MB231 tumors ( 15 B) in nu/nu mice with cMAG-1 and mMAG-1.
  • the arrow indicates the date mMAG-1 was injected in the control group mice.
  • FIGS. 16A and 16B show internalization of the mMAG-1 antibody ( FIG. 16A ) and the 520C-9 positive control antibody ( FIG. 16B ) in SKBr3 cells.
  • FIG. 17 shows synergistic inhibition of SCLC H82 tumor growth after chemotherapy with cyclophosphamide and treatment with mMAG-1.
  • the present disclosure describes, inter alia, the detection of NRSA in provasopressin-expressing cancers using provasopressin-binding antibodies, such as MAG-1, MAG-2, MAG-3, MAG-4, and MAG-5, antigen-binding portions thereof, and other related forms of antibodies or mimics thereof.
  • provasopressin-binding antibodies such as MAG-1, MAG-2, MAG-3, MAG-4, and MAG-5, antigen-binding portions thereof, and other related forms of antibodies or mimics thereof.
  • These antibodies may bind the C-terminal portion of the VAG region of provasopressin, and may have similar specificity and/or affinity as that of MAG-1.
  • MAG-1 was described in PCT Publication No. WO04/006860, which is herein incorporated by reference in its entirety.
  • MAG-2 through MAG-5 have been described in more detail in U.S. Provisional Application 61/127,089 and PCT publication WO 2009/137113A2, which are both incorporated herein by reference in their entirety.
  • MAG-1 recognizes the ⁇ 20 kDa and ⁇ 40 kDa NRSA proteins in cultured SCLC cell lysate by Western analysis, while immunofluorescent cytometric and microscopic analyses indicates that it binds to the surface of these cells.
  • the ⁇ 20 kDa and ⁇ 40 kDa NRSA proteins were detected in the lysate of human SCLC tumor biopsy samples by Western analysis using MAG-1, but they were not detected in the lysate of non-tumor human lung tissue.
  • MAG-1 reacts with human SCLC tumor, but not with normal lung tissue. Since NRSA is not typically found on the surface of normal cells, it is an excellent target in an antibody-based approach for tumor localization in the diagnosis and therapy of cancers expressing NRSA, such as neuroendocrine, prostate, and pancreatic cancers.
  • the invention described herein provides reagents and methods of using such reagents for treating or diagnosing patients having pro-VP expressing cancer or tumor.
  • administering is defined herein as providing a composition to a patient in a manner that results in the composition coming into contact with the patient's body, in a manner that permits or leads to a desired therapeutic effect.
  • Such an administration can be by any route, including, without limitation, subcutaneous, intradermal, intravenous, intra-arterial, intraperitoneal, intramuscular, and/or topical.
  • amino acid residue is known in the art.
  • the abbreviations used herein for designating the amino acids and the protective groups are based on recommendations of the IUPAC-IUB Commission on Biochemical Nomenclature (see Biochemistry (1972) 11:1726-1732).
  • the amino acids used are those naturally occurring amino acids found in proteins, or the naturally occurring anabolic or catabolic products of such amino acids which contain amino and carboxyl groups.
  • amino acid side chains include side chains selected from those of the following amino acids: glycine, alanine, valine, cysteine, leucine, isoleucine, serine, threonine, methionine, glutamic acid, aspartic acid, glutamine, asparagine, lysine, arginine, proline, histidine, phenylalanine, tyrosine, and tryptophan.
  • an amino acid may be modified by post-translational modifications, such as glycosylation, phosphorylation, deamidation, isomerization, pyroglutamic acid modification, and oxidation (e.g., methionine oxidation).
  • the term “antibody” refers to an immunoglobulin molecule.
  • the term “antibody” encompasses monoclonal and polyclonal antibodies.
  • the antibody may be an IgG, an IgM, an IgE, an IgA or an IgD molecule.
  • the antibody is an IgG and is an IgG1, IgG2, IgG3 or IgG4 subtype.
  • the class and subclass of antibodies may be determined by any method known in the art, for example, by using antibodies that are specific for a particular class and subclass of antibody. Such antibodies are available commercially.
  • the class and subclass can be determined by ELISA or Western blot as well as other techniques.
  • the class and subclass may be determined by sequencing all or a portion of the constant domains of the heavy and/or light chains of the antibodies, comparing their amino acid sequences to the known amino acid sequences of various class and subclasses of immunoglobulins, and determining the class and subclass of the antibodies.
  • antibodies encompasses immunoglobulins produced in vivo, as well as those produced in vitro by, for example, a hybridoma, and antigen binding fragments (e.g., Fab′ preparations) of such immunoglobulins, as well as to recombinantly expressed antigen binding proteins, including immunoglobulins, chimeric immunoglobulins, “humanized” immunoglobulins such as COMPOSITE HUMAN ANTIBODIESTM immunoglobulins, antigen binding portions of such immunoglobulins, single chain antibodies, and other recombinant proteins containing antigen binding domains derived from immunoglobulins.
  • antigen binding fragments e.g., Fab′ preparations
  • antibodies also include antigen binding synthetic peptides comprising sequences derived from the sequences of immunoglobulin antigen binding domains. In other embodiments, “antibodies” exclude such antigen binding synthetic peptides. In some embodiments, the anti-vasopressin antibody or antigen-binding portion thereof contains non-natural amino acid residues and/or is conjugated to additional molecules such as PEG.
  • human antibody is intended to include antibodies having variable and constant regions obtained or derived from human germline immunoglobulin sequences.
  • the human antibodies of the invention may include amino acid residues not encoded by human germline immunoglobulin sequences or sequences of actual human DNA (e.g., human antibodies of the invention may include amino acid mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo), for example in the CDRs and in particular CDR3.
  • human antibody as used herein, is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences.
  • recombinant human antibody is intended to include all human antibodies that are prepared, expressed, created or isolated by recombinant means, such as antibodies expressed using a recombinant expression vector transfected into a host cell (described further below), antibodies isolated from a recombinant, combinatorial human antibody library (described further below), antibodies isolated from an animal (e.g., a mouse) that is transgenic for human immunoglobulin genes (see e.g., Taylor, L. D., et al. (1992) Nucl. Acids Res. 20:6287-6295) or antibodies prepared, expressed, created or isolated by any other means that involves splicing of human immunoglobulin gene sequences to other DNA sequences.
  • Such recombinant human antibodies have variable and constant regions derived from human germline immunoglobulin sequences.
  • such recombinant human antibodies are subjected to in vitro mutagenesis (or, when an animal transgenic for human Ig sequences is used, in vivo somatic mutagenesis) and thus the amino acid sequences of the VH and VL regions of the recombinant antibodies are sequences that, while derived from and related to human germline VH and VL sequences, may not naturally exist within the human antibody germline repertoire in vivo.
  • an “isolated antibody,” as used herein, is intended to refer to an antibody that is substantially free of other antibodies having different antigenic specificities (e.g., an isolated antibody that specifically binds abnormal vasopressin V2 receptor is substantially free of antibodies that specifically bind antigens other than the abnormal vasopressin V2 receptor, including the wild-type vasopressin V2 receptor).
  • An isolated antibody that specifically binds abnormal vasopressin V2 receptor may, however, have cross-reactivity to other antigens, such as abnormal vasopressin V2 receptor molecules from other species.
  • an isolated antibody may be substantially free of other cellular material and/or chemicals.
  • the “antigen-binding portion thereof” of an anti-provasopressin antibody refers to a portion of an anti-provasopressin antibody that binds to provasopressin with substantial affinity.
  • Substantial affinity includes affinity that is at least 1/100, 1/50, 1/20, 1/10, 1 ⁇ 5, or 1 ⁇ 2 the affinity of the (native) antibody for provasopressin.
  • Antigen-binding portions may be produced by recombinant DNA techniques or by enzymatic or chemical cleavage of intact antibodies.
  • Antigen-binding portions include, inter alia, Fab, Fab′, F(ab′)2, Fv, dAb, and complementarity determining region (CDR) fragments, single-chain antibodies (scFv), single domain antibodies, chimeric antibodies, diabodies and polypeptides that contain at least a portion of an immunoglobulin that is sufficient to confer specific antigen binding to the polypeptide.
  • CDR complementarity determining region
  • biological sample refers to a sample taken from the body of a patient. Such samples include tissue biopsy sample, blood samples, urine samples, and the like.
  • VAG vasopressin-human glycopeptide
  • cancer refers to a condition in which a cell in a patient's body undergoes abnormal, uncontrolled proliferation. “Cancer” also refers to cancerous or malignant tumor tissues. In certain embodiments, the cancer is malignant. Non-limiting examples of cancers include SCLC, breast cancer, ovarian cancer.
  • tumor is used to mean a condition in which a cell in a patient's body undergoes abnormal, uncontrolled proliferation.
  • the tumor is malignant.
  • the tumor is benign.
  • Non-limiting example of tumor include hyperplasia.
  • “Homology” is a measure of the identity of nucleotide sequences or amino acid sequences. In order to characterize the homology, subject sequences are aligned so that the highest percentage homology (match) is obtained, after introducing gaps, if necessary, to achieve maximum percent homology. N- or C-terminal extensions shall not be construed as affecting homology. “Identity” per se has an art-recognized meaning and can be calculated using published techniques. Computer program methods to determine identity between two sequences, for example, include DNAStar® software (DNAStar Inc. Madison, Wis.); the GCG® program package (Devereux, J., et al.
  • the parameters are set such that the percentage of identity is calculated over the full length of the reference nucleotide sequence or amino acid sequence and that gaps in homology of up to about 90% of the total number of nucleotides in the reference sequence are allowed.
  • a “humanized” antibody or antigen-binding portion thereof, as used herein, is an antibody originally generated in a non-human animal, where the non-human animal content (especially the portion not directly responsible for antigen-binding, e.g., the non-CDR region) has been reduced or replaced by corresponding human sequence, by altering the original amino acid sequence, or a fragment of the antibody.
  • the non-human animal content may be less than 50%, 40%, 30%, 20%, 10%, or 5%.
  • the six CDRs of the heavy and light chains and a limited number of structural amino acids of the murine monoclonal antibody are grafted by recombinant technology to the CDR-depleted human IgG scaffold.
  • a humanized antibody may also be a fully human antibody, which may be made in humanized mice resulting in antibodies that do not contain any mouse sequences.
  • chimeric, humanized or primatized (CDR-grafted) antibodies comprising portions derived from different species or fully human antibodies, are also encompassed by the present disclosure.
  • the various portions of these antibodies can be joined together chemically by conventional techniques, or can be prepared as a contiguous protein using genetic engineering techniques.
  • nucleic acids encoding a chimeric or humanized chain can be expressed to produce a contiguous protein. See, e.g., Cabilly et al., U.S. Pat. No. 4,816,567; Cabilly et al., European Patent No.
  • Boss et al. U.S. Pat. No. 4,816,397; Boss et al., European Patent No. 0,120,694; Neuberger, M. S. et al., WO 86/01533; Neuberger, M. S. et al., European Patent No. 0,194,276 B1; Winter, U.S. Pat. No. 5,225,539; and Winter, European Patent No. 0,239,400 B1. See also, Newman, R. et al., BioTechnology, 10: 1455-1460 (1992), regarding primatized antibody. See, e.g., Ladner et al., U.S. Pat. No. 4,946,778; and Bird, R. E. et al., Science, 242: 423-426 (1988)), regarding single chain antibodies.
  • the term “inappropriately express” refers to substantial expression of a gene (or protein) that occurs in a cell type that does not ordinarily substantially express that gene (or protein).
  • Provasopressin is normally expressed only in the hypothalamus, so substantial expression of provasopressin outside the hypothalamus is considered inappropriate expression of provasopressin.
  • the expression difference is quantitative, the expression levels are preferably statistically significantly different (e.g., p ⁇ 0.05, or p ⁇ 0.01).
  • label refers to incorporation of another molecule in the antibody, antigen-binding portion thereof, or peptide.
  • the label is a detectable marker, e.g., incorporation of a radiolabeled amino acid.
  • a detectable marker e.g., incorporation of a radiolabeled amino acid.
  • labels for polypeptides include, but are not limited to, the following: radioisotopes or radionuclides, fluorescent labels, enzymatic labels, chemiluminescent markers, biotinyl groups, predetermined polypeptide epitopes recognized by a secondary reporter (e.g., leucine zipper pair sequences, binding sites for secondary antibodies, metal binding domains, epitope tags), magnetic agents, and toxins.
  • a secondary reporter e.g., leucine zipper pair sequences, binding sites for secondary antibodies, metal binding domains, epitope tags
  • MAG-1 as used herein refers to the monoclonal antibody that is produced by the hybridoma having ATCC Number PTA-5322.
  • a “patient” or “subject” to be treated by the subject methods may mean either a human or non-human animal, such as primates, mammals, vertebrates, rodents, etc.
  • phrases “pharmaceutically acceptable carrier” is art-recognized, and includes, for example, pharmaceutically acceptable materials, compositions or vehicles, such as a liquid or solid filler, diluent, solvent or encapsulating material involved in carrying or transporting any subject composition, from one organ, or portion of the body, to another organ, or portion of the body.
  • a pharmaceutically acceptable carrier is non-pyrogenic.
  • provasopressin-binding antibody refers to an antibody that binds provasopressin with high affinity.
  • exemplary provasopressin-binding antibodies include MAG-1 (described in US Application Publication No. 2008-0050376 and produced by the hybridoma having ATCC Number PTA-5322), MAG-2, MAG-3, MAG-4, and MAG-5.
  • the provasopressin-binding antibodies include Boris and humanized antibodies derived from Boris.
  • the provasopressin-binding antibodies include antibodies having CDR-H3 and CDR-L3 regions identical to that of any one of MAG-1, MAG-2, MAG-3, MAG-4, or MAG-5.
  • the provasopressin-binding antibodies include antibodies having CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 regions identical to that of any one of MAG-1, MAG-2, MAG-3, MAG-4, or MAG-5.
  • the provasopressin-binding antibodies include antibodies having LCVR (light chain variable region) and HLVR (heavy chain variable region) identical to that of any one of MAG-1, MAG-2, MAG-3, MAG-4, or MAG-5.
  • the provasopressin-binding antibodies include antibodies having a single Ala substitution in any one of the CDR3 residues in the light chain and/or heavy chain sequence of any one of MAG-1, MAG-2, MAG-3, MAG-4, or MAG-5. In certain embodiments, the provasopressin-binding antibodies include antibodies having 2, 3, 4, or 5 Ala substitutions in any one of the CDR3 residues in the light chain and/or heavy chain sequence of any one of MAG-1, MAG-2, MAG-3, MAG-4, or MAG-5.
  • the provasopressin-binding antibodies include antibodies having a single conserved amino acid substitution in any one of the CDR3 residues in the light chain and/or heavy chain sequence of any one of MAG-1, MAG-2, MAG-3, MAG-4, or MAG-5.
  • the provasopressin-binding antibodies include antibodies having 2, 3, 4, or 5 conserved amino acid substitutions in any one of the CDR3 residues in the light chain and/or heavy chain sequence of any one of MAG-1, MAG-2, MAG-3, MAG-4, or MAG-5.
  • no more than one to five conservative amino acid substitutions are made within the VL and/or VH CDR3 domains.
  • conservative amino acid substitutions are made within the VL and/or VH CDR3 domains. Additionally, conservative amino acid substitutions (excluding Ala substitution) are not made at amino acid positions critical for antigen binding (e.g., those positions the substitution of which results in at least about 10-fold loss/increase in K d and/or k off values).
  • a “conservative amino acid substitution,” as used herein, is one in which one amino acid residue is replaced with another amino acid residue having a similar side chain.
  • Families of amino acid residues having similar side chains have been defined in the art, including basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). See Table
  • Provasopressin-binding antibodies may also include single chain (scFv) antibodies.
  • the antibodies herein may be IgG antibodies, including IgG1, IgG2, IgG3, or IgG4 antibodies.
  • the antibody binds to provasopressin selectively.
  • provasopressin-expressing cancer refers to a cancer that displays substantial expression of provasopressin.
  • the cancer may, for example, express at least 2, 5, 10, 20, 50, 100, 200, 500, or 1000-fold more provasopressin than a corresponding wild-type tissue.
  • the cancer may be benign or malignant, may be (locally) invasive and/or metastatic.
  • provasopressin-expressing cancer preferably expresses provasopressin on the surface of cancer/tumor cells.
  • provasopressin in a cancer or tumor sample may be determined by any of art recognized methods, including immunohistochemistry, Westemblot, etc.
  • the cancer is not small cell lung cancer (SCLC) or breast cancer.
  • selective refers to a macromolecule (such as an antibody or antigen-binding portion thereof) that binds to its desired target (provasopressin of a fragment thereof) with a K d that is less than 2-fold, 5-fold, and preferably 10-, 20-, 50-, 100-, 200, 500-, or 1000-fold the K d of that antibody or antigen-binding portion thereof for any other wild-type human protein.
  • a “therapeutically effective amount” refers to an effective amount of composition for causing a respective desired therapeutic effect, such as the tumor-/cancer-specific killing of tumor or cancer cells in a patient, eliminating one or more tumor/cancer cells, preventing said cells from proliferating, or inhibiting the rate of proliferation of said cells.
  • the therapeutically effective amount possesses a reasonable benefit/risk ratio applicable to the medical treatment.
  • treating a patient suffering from tumor/cancer, it is meant that at least one of the patient's symptoms is partially or totally alleviated, remain static, or its progression retarded, following treatment according to the methods herein.
  • a patient that has been treated can exhibit a partial or total alleviation of symptoms and/or tumor load, either temporarily or permanently.
  • the term “treatment” may encompass prophylaxis use, therapy and cure. In certain embodiments, the term “treatment” may exclude prophylaxis use, therapy and cure.
  • the methods herein may use various provasopressin-binding agents, such as anti-proVP binding antibodies or antigen-binding portions thereof.
  • provasopressin-binding antibody include monoclonal or polyclonal antibodies. Such antibodies may be mouse antibodies, human antibodies, chimeric antibodies (such as human-mouse chimeric antibodies), or humanized antibodies.
  • the antigen-binding portion thereof may include single chain scFv, Fab, F(ab′) 2 , Fd, Fv, dAb, bispecific antibodies, or other antibody fragments that retains all or substantially all binding affinity (e.g., no worse than 5, 10, 20, 50, 100, 200, 500 fold reduction, as measured by K d and/or k off ) of a full length antibody, such as an IgG1, IgG2, IgG3, or IgG4 antibody.
  • the antibody or its antigen-binding portion thereof may bind, preferably specifically, to any epitope of the GRSA or NRSA antigen or pro-VP, including the mature VP region, mature VP-NP region, mature VAG region, or linker regions therebetween (such as the link between vasopressin and neurophysin moieties).
  • the antibody may also be specific for epitopes comprising post-translational modifications, including glycosylation.
  • the antibody may be in its native form. In certain embodiments, the antibody may be in forms containing a covalently or non-covalently conjugated moiety, such as an attached toxin, enzyme, fluorescent label, or radionuclide.
  • a covalently or non-covalently conjugated moiety such as an attached toxin, enzyme, fluorescent label, or radionuclide.
  • the antibody or antigen-binding portion thereof comprises a purification tag.
  • a purification tag may be used to facilitate purification of the antibody or antigen-binding portion thereof during the manufacturing process.
  • Exemplary purification tag peptides include His, GST, TAP, FLAG, myc, HA, MBP, VSV-G, thioredoxin, V5, avidin, streptavidin, BCCP, Calmodulin, Nus, and S tags.
  • One exemplary antibody MAG-1 interacts with the GRSA antigen, a form of provasopressin present as a surface product on pro-VP expressing cancers.
  • the subject antibody or antigen-binding portion thereof may be immunoreactive with the isolated polypeptide of SEQ ID NO: 1, SEQ ID NO: 5, and/or SEQ ID NO: 6.
  • Provasopressin-binding antibodies include the monoclonal antibody produced by the hybridoma having ATCC Number PTA-5322, wherein the monoclonal antibody is MAG-1.
  • Provasopressin-binding antibodies also include the similarly produced monoclonal antibodies MAG-2, MAG-3, MAG-4, and MAG-5 (see below).
  • the provasopressin-binding antibody is selective for provasopressin. In other embodiments, the provasopressin-binding antibody is selective for a particular epitope of provasopressin. For example, it may immunoreact with SEQ ID NO: 1 but show no substantial immunoreactivity with SEQ ID NO: 6. Other provasopressin-binding antibodies immunoreact with SEQ ID NO: 6, but show no substantial immunoreactivity SEQ ID NO: 1.
  • the subject antibody may also include variants of the MAG-1, MAG-2, MAG-3, MAG-4, and/or MAG-5 antibodies.
  • Variants of these antibodies, or antigen-binding portions thereof, and peptides may have an amino acid sequence that is different by one or more amino acid substitutions from the amino acid sequence of MAG-1, MAG-2, MAG-3, MAG-4, or MAG-5.
  • Embodiments which comprise amino acid deletions and/or additions are also contemplated.
  • the variant may have conservative changes (amino acid similarity), wherein a substituted amino acid has similar structural or chemical properties, for example, the replacement of leucine with isoleucine.
  • Amino acid substitutions may be made, for instance, on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues as long as a biological and/or pharmacological activity of the native molecule is retained.
  • Negatively charged amino acids include aspartic acid and glutamic acid; positively charged amino acids include lysine and arginine; amino acids with uncharged polar head groups having similar hydrophilicity values include leucine, isoleucine, and valine; amino acids with aliphatic head groups include glycine, alanine; asparagine, glutamine, serine; and amino acids with aromatic side chains include tryptophan, phenylalanine, and tyrosine.
  • HAMA human anti-mouse antibody
  • the HAMA response may be triggered when an antibody has epitopes recognized by human T cells.
  • the antibodies described herein preferably are not recognized well by human T cells.
  • HAMA type human anti-non-human antibody
  • Antibodies from other non-human animals have similar deleterious effects to a patient.
  • the antibodies described herein may be humanized by any means known in the art.
  • variable regions By manipulating the nucleic acid molecules encoding antibody H and L chains, it is possible to incorporate non-human variable regions into antibodies otherwise made up of human constant regions.
  • the resulting antibodies are referred to as “chimeric antibodies,” and are typically less prone to eliciting HAMA type responses than are the non-human antibodies from which the variable regions are derived.
  • An alternative to eliminating the potential of a non-human antibody to elicit a HAMA type response is to “humanize” it, i.e., to replace its non-human framework regions with human ones.
  • One way of achieving such humanization involves the insertion of polynucleotide fragments encoding the non-human CDRs of the antibody to be humanized into a nucleic acid molecule encoding an otherwise human antibody (with human constant regions if desired) so as to replace the human CDRs and to use the resulting nucleic acid molecule to express the encoded “humanized” antibody. If this process results in a loss of antibody-epitope affinity, selected humanized residues may be mutated back to their identity in the non-human antibody.
  • a humanized antibody can be an antibody derived from a non-human species, in which certain amino acids in the framework and constant domains of the heavy and light chains have been mutated so as to reduce or abolish an immune response in humans.
  • a humanized antibody may be produced by fusing the constant domains from a human antibody to the variable domains of a non-human species. Examples of how to make humanized antibodies may be found in U.S. Pat. Nos. 6,054,297, 5,886,152 and 5,877,293 (incorporated by reference).
  • a humanized antibody may comprise portions of immunoglobulins of different origin. For example, at least one portion can be of human origin.
  • the humanized antibody can comprise portions derived from an immunoglobulin of nonhuman origin with the requisite specificity, such as a mouse, and from immunoglobulin sequences of human origin (e.g., a chimeric immunoglobulin), joined together chemically by conventional techniques (e.g., synthetic) or prepared as a contiguous polypeptide using genetic engineering techniques (e.g., DNA encoding the protein portions of the chimeric antibody can be expressed to produce a contiguous polypeptide chain).
  • a humanized antibody may be created in a transgenic or humanized animal expressing the human antibody genes (see Lonberg, N. “Transgenic Approaches to Human Monoclonal Antibodies,” Handbook of Experimental Pharmacology (1994)113: 49-101) (incorporated by reference).
  • humanized immunoglobulin is an immunoglobulin containing one or more immunoglobulin chains comprising a CDR of non-human origin (e.g., one or more CDRs derived from an antibody of nonhuman origin) and a framework region derived from a light and/or heavy chain of human origin (e.g., CDR-grafted antibodies with or without framework changes). Chimeric or CDR-grafted single chain antibodies are also encompassed by the term humanized immunoglobulin.
  • CDR of non-human origin e.g., one or more CDRs derived from an antibody of nonhuman origin
  • framework region derived from a light and/or heavy chain of human origin
  • Chimeric or CDR-grafted single chain antibodies are also encompassed by the term humanized immunoglobulin.
  • COMPOSITE HUMAN ANTIBODYTM technology which is described in detail in WO 2006/082406 (incorporated by reference). Briefly, the CDR regions are left intact or essentially intact.
  • the non-human framework is replaced with a composite humanized framework.
  • the composite humanized framework may be a chimera of several fragments from different endogenous human framework alleles. In this manner, a composite framework may be produced that resembles the antibody's non-human framework more closely than any given endogenous human framework.
  • the antibody of the invention may be fully human antibodies, such as isolated human antibodies.
  • An entirely human antibody should, in theory, not elicit the HAMA reaction, even if used for prolonged periods.
  • Fully human monoclonal autoantibodies may be prepared using human hybridoma techniques (see Boyle et al., Cell. Immunol. 152: 556-568, 1993; Boyle et al., Cell. Immunol. 152: 569-581, 1993; European Patent Application Publication No. 614 984 A2 by Boyle, et al.).
  • the human antibodies have a high affinity for its antigen, which affinity can be measured or calculate by conventional methods, such as Kd or koff values that can be measured by surface plasmon resonance.
  • surface plasmon resonance refers to an optical phenomenon that allows for the analysis of real-time biospecific interactions by detection of alterations in protein concentrations within a biosensor matrix, for example using the BIAcore system (Pharmacia Biosensor AB, Uppsala, Sweden and Piscataway, N.J.).
  • BIAcore Phharmacia Biosensor AB, Uppsala, Sweden and Piscataway, N.J.
  • the subject human antibodies may be produced by recombinant DNA technology using procedures well known in the art.
  • Recombinant human antibodies preferably have high affinity (e.g., K d is about 10 ⁇ 7 M, 10 ⁇ 8 M, 10 ⁇ 9 M, 10 ⁇ 10 M or less) and a slow k off rate (e.g., k off is about 10 ⁇ 2 s ⁇ 1 , 10 ⁇ 3 s 1 , 10 ⁇ 4 s ⁇ 1 , 10 ⁇ 4 s ⁇ 1 ).
  • the subject pro-VP antagonists include antibodies, antigen-binding portions thereof, and variants thereof with amino acid sequence substitutions, the antagonists are not so limited.
  • Other antagonists, including protein or nucleic acid based antagonists, may also be used in the subject methods.
  • the pro-VP antagonist is an aptamer. Since the identification of the first RNA aptamer as an antagonist against bacterial phage T4 DNA polymerase in 1990, the SELEX (systematic evolution of ligands by exponential enrichment) process and its variations have been used successfully to identify aptamers for more than 100 diverse target molecules, including organic dyes, amino acids, biological cofactors, antibiotics, peptides, proteins, or even whole viruses (Bell et al., J. Biol. Chem. 273: 14309-14314, 1998; Gal et al., Eur. J. Biochem. 252: 553-562, 1998; Kraus et al., J.
  • the SELEX process provides a powerful method for the screening of large libraries of oligonucleotides, with diversities of up to 10 15 different molecules, for specific ligand-binding nucleic acids, which in many cases have been shown to not only bind a certain target protein, but also to inhibit its biological function.
  • Such isolated aptamers routinely have high affinity and specificity for their respective targets, and are useful for various therapeutic and/or diagnostic applications.
  • a wide spectrum of chemical modifications of nucleotides is known in the art, which can greatly increase the stability of RNA molecules in biological materials, thus considerably enhancing their application potential.
  • any potential insufficient stability of the identified nucleic acids as therapeutic agents can easily be overcome by using libraries of chemically modified nucleic acids, such as 2′-fluoro- or 2′-amino-2′-deoxypyrimidine-containing nucleic acids. Such modifications have been shown to be compatible with the enzymatic steps of the SELEX process.
  • Other strategies which circumvent the stability problem of RNA or DNA include the so-called mirror-image, or Spiegelmer, approach by exploiting nuclease resistance of the enantiomer of naturally occurring nucleic acids (KLU ⁇ MANN et al., Nat. Biotechnol. 14: 1112-1115, 1996; Nolte et al., Nat. Biotechnol. 14: 1116-1119, 1996).
  • Exemplary aptamers that may be used in the instant invention were identified by Williams et al. in 1997 using the SELEX method (Williams et al., Proc. Natl. Acad. Sci. U.S.A. 94: 11285-11290, 1997, incorporated by reference), as L-ssDNA ligands to vasopressin.
  • D-DNA ligands have been selected using D-vasopressin as a target molecule.
  • the enantiomer of the winning D-ssDNA aptamer designated as L-ssDNA aptamer, has been synthesized and its ability to bind L-vasopressin was demonstrated.
  • the subject invention provides a method to identify aptamers that selectively bind pro-VP or fragments thereof, the method comprising contacting a target protein, such as pro-VP, with a library of candidate aptamers, and selectively identifying/isolating/enriching for aptamers that specifically bind the target protein.
  • the identified aptamer may be similarly labeled by moieties including fluorescent dye, radioactive moiety, or a therapeutic agent, as described herein for antibody-based antagonists.
  • Such labeled aptamers can be similarly used in the diagnostic and/or therapeutic applications of the invention, in a similar way the antibody-based pro-VP antagonists are used.
  • the pro-VP antagonist is a scaffold-derived binding protein specific for pro-VP or any of its epitopes.
  • the most promising scaffolds with broader applicability include protein A, the lipocalins, a fibronectin domain, an ankyrin consensus repeat domain, and thioredoxin.
  • Corresponding binding proteins are not only of interest as research reagents or for separation in biotechnology but also as potential biopharmaceuticals, especially in the areas of cancer, autoimmune and infectious diseases as well as for in vivo diagnostics.
  • the subject invention provides a method to identify scaffold-derived binding proteins that selectively bind pro-VP or fragments thereof, the method comprising contacting a target protein, such as pro-VP, with a library of candidate scaffold-derived binding proteins, and selectively identifying/isolating/enriching for scaffold-derived binding proteins that specifically bind the target protein.
  • the identified scaffold-derived binding proteins may be similarly labeled by moieties including fluorescent dye, radioactive moiety, or a therapeutic agent, as described herein for antibody-based antagonists.
  • Such labeled scaffold-derived binding proteins can be similarly used in the diagnostic and/or therapeutic applications of the invention, in a similar way the antibody-based pro-VP antagonists are used.
  • the scaffold-derived binding proteins are derived from a scaffold of protein A, a lipocalin, a fibronectin domain, an ankyrin consensus repeat domain, or thioredoxin.
  • the pro-VP antagonist is a fusion protein that functions similarly as an antibody.
  • the anti-Rheumatoid drug etanercept (trade name ENBREL®) treats autoimmune diseases by binding to tumor necrosis factor alpha (TNF ⁇ ) as a TNF ⁇ inhibitor. It is a recombinantly expressed as a fusion protein between the human soluble TNF receptor 2 and the Fc component of human immunoglobulin G1 (IgG1).
  • IgG1 human immunoglobulin G1
  • Such a fusion protein functions similarly as the human-mouse chimeric antibody against TNF ⁇ , such as infliximab (trade name REMICADE®).
  • any of the above protein based pro-VP antagonists can be made as part of a fusion protein and be used in the methods of the invention.
  • a soluble vasopressin receptor may be fused to the Fc region as in etanercept, and be used as a pro-VP antagonist in the instant invention.
  • the linker can facilitate enhanced flexibility, and/or reduce steric hindrance between any two fragments.
  • the linker can also facilitate the appropriate folding of each fragment to occur.
  • the linker can be of natural origin, such as a sequence determined to exist in random coil between two domains of a protein.
  • An exemplary linker sequence is the linker found between the C-terminal and N-terminal domains of the RNA polymerase a subunit.
  • Other examples of naturally occurring linkers include linkers found in the lcI and LexA proteins.
  • the amino acid sequence may be varied based on the preferred characteristics of the linker as determined empirically or as revealed by modeling. For instance, in addition to a desired length, modeling studies may show that side groups of certain amino acids may interfere with the biological activity, e.g. DNA binding or transcriptional activation, of the protein. Considerations in choosing a linker include flexibility of the linker, charge of the linker, and presence of some amino acids of the linker in the naturally-occurring subunits.
  • the linker can also be designed such that residues in the linker contact DNA, thereby influencing binding affinity or specificity, or to interact with other proteins.
  • a linker may contain an amino acid sequence which can be recognized by a protease so that the activity of the chimeric protein could be regulated by cleavage.
  • the linker may optionally contain an additional folded domain.
  • the design of a linker involve an arrangement of domains which requires the linker to span a relatively short distance, preferably less than about 10 Angstroms ( ⁇ ). However, in certain embodiments, depending, e.g., upon the selected domains and the configuration, the linker may span a distance of up to about 50 Angstroms.
  • Linkers may be added to the nucleic acid sequences of the heavy and light chains to increase flexibility of the antibody.
  • the linkers are added to connect the VH and VL chains and the varying composition can effect solubility, proteolytic stability, flexibility, and folding.
  • a linker of has the amino sequence GSTSG (SEQ ID NO: 7).
  • a linker has the amino sequence GGSSRSS (SEQ ID NO: 4).
  • Linkers are well-known in the art and can comprise varied amino acid residues depending on the flexibility needed in the resulting recombinant protein to allow for biological activity.
  • the antagonists e.g., antibodies and antigen-binding portions
  • the antagonists can be used, for example, for immuno-based targeting of tumors and delivery of chemotoxic/radiologic agents.
  • Provasopressin-expressing tumors can be localized and imaged using an antibody to the provasopressin protein.
  • antibodies, antigen-binding portions thereof, and their derivatives could be radiolabeled, conjugated to or used in conjunction with chemotoxic agents, or serve as an attractor for endogenous immune system cells to kill provasopressin-expressing tumors (NRSA/GRSA-expressing tumors).
  • Cancer vaccines may be based on tumor antigens, such as NRSA and GRSA.
  • vaccine strategies based on NRSA/GRSA such as anti-antibodies or utilizing antigenic motifs on the NRSA/GRSA structure, could be developed that would enable the initial prevention and/or recurrence of these diseases.
  • label is used to mean a detectable label which is used to visualize the binding of an antibody to its target protein or receptor.
  • antibodies, antigen-binding portions thereof, and peptides may be labeled with, for example, a radiolabel, an iron-related compound, a fluorescent label, or a toxin which would kill or inhibit proliferation of the cell to which it binds.
  • Radiolabels and toxins are well known in the art.
  • Radiolabels include, for example, 32 P, 33 P, 43 K, 47 Sc, 52 Fe, 57 Co, 64 Cu, 67 Ga, 67 Cu, 68 Ga, 71 Ge, 75 Br, 76 Br, 77 Br, 77 As, 77 Br, 81 Rb/ 81M Kr, 87M Sr, 90 Y, 97 Ru, 99 Tc, 100 Pd, 101 Rh, 103 Pb, 105 Rh, 109 Pd, 111 Ag, 111 In, 113 In, 119 Sb 121 Sn, 123 I, 125 I, 127 Cs, 128 Ba, 129 Cs, 131 I, 131 Cs, 143 Pr, 153 Sm, 161 Tb, 166 Ho, 169 Eu, 177 Lu, 186 Re, 188 Re, 189 Re, 191 Os, 193 Pt, 194 Ir, 197 Hg, 199 Au, 203 Pb, 211 At, 212 Pb, 212 Bi and 213
  • Non-limiting examples of toxins include, for example, ricin A chain (ricin toxin), Pseudomonas exotoxin (PE), diphtheria toxin (DT), Clostridium perfringens phospholipase C (PLC), bovine pancreatic ribonuclease (BPR), pokeweed antiviral protein (PAP), abrin, abrin A chain (abrin toxin), cobra venom factor (CVF), gelonin (GEL), saporin (SAP), modeccin, viscumin and volkensin.
  • ricin A chain ricin toxin
  • PE Pseudomonas exotoxin
  • DT diphtheria toxin
  • PLC Clostridium perfringens phospholipase C
  • BPR bovine pancreatic ribonuclease
  • PAP pokeweed antiviral protein
  • abrin abrin
  • abrin A chain abri
  • Non-limiting examples of fluorescent labels include, for example, FITC, Texas Red, phycoerythrin (PE), cytochrome c, Cy3, and Cy5.
  • Non-limiting examples of metals such as iron-related compounds include, for example, magnetic iron-oxide particles, ferric or ferrous particles, Fe 2 O 3 , and Fe 3 O 4 .
  • Iron-related compounds and methods of labeling antibodies and polypeptides can be found, for example, in U.S. Pat. Nos. 4,101,435 and 4,452,773, and U.S. published applications 20020064502 and 20020136693, all of which are hereby incorporated by reference in their entirety.
  • biotin followed by streptavidin-alkaline phosphatase (AP), horseradish peroxidase (HRP) are contemplated.
  • antibodies, antigen binding portions thereof, and peptides are well known in the art.
  • the antibodies, antigen binding portions thereof, and peptides are labeled with a radiolabel or toxin
  • the antibodies, antigen binding portions thereof, and peptides can be prepared as pharmaceutical compositions which are useful for therapeutic treatment of patients exhibiting increased levels of provasopressin wherein the pharmaceutical compositions are administered to the patient in an effective amount.
  • the antibodies, antigen binding portions, or peptides are coupled to a polymer or a functionalized polymer (e.g., a polymer conjugated to another molecule).
  • a polymer or a functionalized polymer e.g., a polymer conjugated to another molecule.
  • a polymer or a functionalized polymer e.g., a polymer conjugated to another molecule.
  • water soluble polymers such as polyglutamic acid or polyaspartic acid
  • conjugated to a drug such as a chemotherapeutic or antiangiogenic agent, including, for example, paclitaxel or docetaxel.
  • the linkage is hydrolys able, e.g., such as may be provided by use of an amide or ester group in the linking moiety.
  • the subject antibodies, antigen binding portions thereof, or peptides can be coupled with an agent useful in imaging tumors.
  • agents include: metals; metal chelators; lanthanides; lanthanide chelators; radiometals; radiometal chelators; positron-emitting nuclei; microbubbles (for ultrasound); liposomes; molecules microencapsulated in liposomes or nanosphere; monocrystalline iron oxide nanocompounds; magnetic resonance imaging contrast agents; light absorbing, reflecting and/or scattering agents; colloidal particles; fluorophores, such as near-infrared fluorophores.
  • such secondary functionality will be relatively large, e.g., at least 25 amu in size, and in many instances can be at least 50, 100 or 250 amu in size.
  • the secondary functionality is a chelate moiety for chelating a metal, e.g., a chelator for a radiometal or paramagnetic ion. In preferred embodiments, it is a chelator for a radionuclide useful for radiotherapy or imaging procedures.
  • Radionuclides useful within the compositions and methods herein include gamma-emitters, positron-emitters, Auger electron-emitters, X-ray emitters and fluorescence-emitters, with beta- or alpha-emitters preferred for therapeutic use.
  • radionuclides useful as toxins in radiation therapy include: 32 P, 33 P, 43 K, 47 Sc, 52 Fe, 57 Co, 64 Cu, 67 Ga, 67 Cu, 68 Ga, 71 Ge, 75 Br, 76 Br, 77 Br, 77 As 77 As, 77 Br, 81 Rb/ 81M Kr, 87M Sr, 90 Y, 97 Ru, 99 Tc, 100 Pd, 101 Rh 103 Pb, 105 Rb, 109 Pd, 111 Ag, 111 In, 113 In, 119 Sb, 121 Sn, 123 I, 125 I, 127 Cs, 128 Ba, 129 Cs, 131 I, 131 Cs, 143 Pr, 153 Sm, 161 Tb, 166 Ho, 169 Eu, 177 Lu, 186 Re, 188 Re, 189 Re, 191 Os 193 Pt, 194 Ir, 197 Hg, 199 Au, 203 Pb, 211 At, 212 Pb, 197
  • Radionuclides include 188 Re, 186 Re, 203 Pb, 212 Pb, 212 Bi, 109 Pd, 64 Cu, 67 Cu, 90 Y, 125 I, 131 I, 77 Br, 211 At, 97 Ru, 105 Rh, 198 Au and 199 Ag, 166 Ho or 177 Lu.
  • radionuclide and “radiolabel” are interchangeable.
  • the modified antibodies, antigen binding portions, and peptides include a chelating agent for technium.
  • the secondary functionality can be a radiosensitizing agent, e.g., a moiety that increases the sensitivity of cells to radiation.
  • radiosensitizing agents include nitroimidazoles, metronidazole and misonidazole (see: DeVita, V. T. Jr. in Harrison's Principles of Internal Medicine, p. 68, McGraw-Hill Book Co., N.Y. 1983, which is incorporated herein by reference).
  • the modified antibodies, antigen binding portions, and peptides that comprise a radiosensitizing agent as the active moiety are administered and localize at the target cell. Upon exposure of the individual to radiation, the radiosensitizing agent is “excited” and causes the death of the cell.
  • the chelator can be a derivative of 1,4,7,10-tetraazacyclododecanetetraacetic acid (DOTA), ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTPA) and 1-p-Isothiocyanato-benzyl-methyl-diethylenetriaminepentaacetic acid (ITC-MX).
  • DOTA 1,4,7,10-tetraazacyclododecanetetraacetic acid
  • EDTA ethylenediaminetetraacetic acid
  • DTPA diethylenetriaminepentaacetic acid
  • ITC-MX 1-p-Isothiocyanato-benzyl-methyl-diethylenetriaminepentaacetic acid
  • These chelators typically have groups on the side chain by which the chelator can be used for attachment to subject antibodies, antigen binding portions, and peptides. Such groups include, e.g., benzylisothiocyanate
  • the chelate moiety is an “N x S y ” chelate moiety.
  • N x S y chelates includes bifunctional chelators that are capable of coordinately binding a metal or radiometal and, preferably, have N 2 S 2 or N 3 S cores. Exemplary N x S y chelates are described, e.g., in Fritzberg et al. (1988) PNAS 85:4024-29; and Weber et al. (1990) Bioconjugate Chem. 1:431-37; and in the references cited therein.
  • the Jacobsen et al. PCT application WO 98/12156 provides methods and compositions, i.e., synthetic libraries of binding moieties, for identifying compounds which bind to a metal atom.
  • the approach described in that publication can be used to identify binding moieties which can subsequently be added to antibodies, antigen binding portions, and peptides to derive the modified antibodies, antigen binding portions, and peptides described herein.
  • Certain of the subject labeled/modified antibodies, antigen binding portions thereof, and peptides can be synthesized, by standard methods known in the art, to provide reactive functional groups which can form acid-labile linkages with, e.g., a carbonyl group of the ligand.
  • suitable acid-labile linkages include hydrazone and thiosemicarbazone functions. These are formed by reacting the oxidized carbohydrate with chelates bearing hydrazide, thiosemicarbazide, and thiocarbazide functions, respectively.
  • base-cleavable linkers which have been used for the enhanced clearance of the radiolabel from the kidneys, can be used. See, for example, Weber et al. 1990 Bioconjug. Chem. 1:431.
  • the coupling of a bifunctional chelate to antibodies, antigen binding portions, and peptides via a hydrazide linkage can incorporate base-sensitive ester moieties in a linker spacer arm.
  • Such an ester-containing linker unit is exemplified by ethylene glycolbis(succinimidyl succinate), (EGS, available from Pierce Chemical Co., Rockford, Ill.), which has two terminal N-hydroxysuccinimide (NHS) ester derivatives of two 1,4-dibutyric acid units, each of which are linked to a single ethylene glycol moiety by two alkyl esters.
  • NHS ester may be replaced with a suitable amine-containing BFC (for example 2-aminobenzyl DTPA), while the other NHS ester is reacted with a limiting amount of hydrazine.
  • the resulting hydrazide is used for coupling to the antibodies, antigen binding portions, and peptides, forming an ligand-BFC linkage containing two alkyl ester functions.
  • Such a conjugate is stable at physiological pH, but readily cleaved at basic pH.
  • Antibodies and antigen binding portions thereof labeled by chelation can be subject to radiation-induced scission of the chelator and to loss of radioisotope by dissociation of the coordination complex.
  • metal dissociated from the complex can be re-complexed, providing more rapid clearance of non-specifically localized isotope and therefore less toxicity to non-target tissues.
  • chelator compounds such as EDTA or DTPA can be infused into patients to provide a pool of chelator to bind released radiometal and facilitate excretion of free radioisotope in the urine.
  • the antibodies and antigen binding portions are coupled to a Boron addend, such as a carborane.
  • carboranes can be prepared with carboxyl functions on pendant side chains, as is well known in the art. Attachment of such carboranes to an amine functionality, e.g., as may be provided on the antibodies, antigen binding portions, and peptides, can be achieved by activation of the carboxyl groups of the carboranes and condensation with the amine group to produce the conjugate.
  • Such modified antibodies, antigen binding portions, and peptides can be used for neutron capture therapy.
  • the antibodies and antigen-binding portions thereof may also be modified with dyes, for example, useful in photodynamic therapy, and used in conjunction with appropriate non-ionizing radiation.
  • dyes for example, useful in photodynamic therapy, and used in conjunction with appropriate non-ionizing radiation.
  • the use of light and porphyrins is also contemplated and their use in cancer therapy has been reviewed by van den Bergh, Chemistry in Britain, 22: 430-437 (1986).
  • One embodiment includes antibodies and antigen binding portions thereof, labeled with a fluorescent label.
  • fluorescent labels include, for example, FITC, PE, Texas Red, fluorescent nanodots, rhodamine, and the like. Techniques for labeling polypeptides and proteins are well-known in the art.
  • One embodiment includes antibodies and antigen binding portions thereof labeled with a metal compound, such as iron, which can be used in MRI imaging and/or for treatment.
  • Iron-containing compounds include both ferrous and ferric-containing compounds, such as ferric-oxides. Specific examples include Fe 2 O 3 and Fe 3 O 4 .
  • Iron-containing compounds and methods of making iron-coupled antibodies and fragments thereof are described in U.S. Pat. Nos. 4,101,435 and 4,452,773 and published U.S. patent applications 2002/0064502 and 2002/0136693, all of which are hereby incorporated by reference in their entireties.
  • the antibodies and antigen binding portions thereof can be covalently or non-covalently coupled to a cytotoxin, chemotherapeutic agent, or other cell proliferation inhibiting compound, in order to localize delivery of that agent to a tumor cell.
  • the agent can be selected from the group consisting of alkylating agents, enzyme inhibitors, proliferation inhibitors, lytic agents, DNA or RNA synthesis inhibitors, membrane permeability modifiers, DNA intercalators, metabolites, dichloroethylsulfide derivatives, protein production inhibitors, ribosome inhibitors, inducers of apoptosis, and neurotoxins.
  • Chemotherapeutics useful as active moieties which when conjugated to antibodies, antigen binding portions, and peptides are specifically delivered to tumorigenic cells are typically, small chemical entities produced by chemical synthesis.
  • Chemotherapeutics include cytotoxic and cytostatic drugs.
  • Chemotherapeutics may include those which have other effects on cells such as reversal of the transformed state to a differentiated state or those which inhibit cell replication. Examples of known, useful cytotoxic agents are listed, for example, in Goodman et al., The Pharmacological Basis of Therapeutics , Sixth Edition, A. G. Gilman et al, eds./Macmillan Publishing Co. New York, 1980 (incorporated by reference).
  • taxanes such as paclitaxel (TAXOL®) and docetaxel (TAXOTERE®); nitrogen mustards, such as mechlorethamine, cyclophosphamide, melphalan, uracil mustard and chlorambucil; ethylenimine derivatives, such as thiotepa; alkyl sulfonates, such as busulfan; nitrosoureas, such as carmustine, lomustine, semustine and streptozocin; triazenes, such as dacarbazine; folic acid analogs, such as methotrexate; pyrimidine analogs, such as fluorouracil, cytarabine and azaribine; purine analogs, such as mercaptopurine and thioguanine; vinca alkaloids, such as vinblastine and vincristine; antibiotics, such as dactinomycin, daunorubicin, doxorubicin,
  • Drugs that interfere with intracellular protein synthesis can also be used; such drugs are known to those skilled in the art and include puromycin, cycloheximide, and ribonuclease.
  • chemotherapeutic agents currently in use in treating cancer possess functional groups that are amenable to chemical cross-linking directly with an amine or carboxyl group of an agent described herein.
  • functional groups that are amenable to chemical cross-linking directly with an amine or carboxyl group of an agent described herein.
  • free amino groups are available on methotrexate, doxorubicin, daunorubicin, cytosinarabinoside, bleomycin, gemcitabine, fludarabine, and cladribine while free carboxylic acid groups are available on methotrexate, melphalan, and chlorambucil.
  • These functional groups that is free amino and carboxylic acids, are targets for a variety of homobifunctional and heterobifunctional chemical cross-linking agents which can crosslink these drugs directly to a free amino group of an antibody, antigen binding portion thereof, or peptide.
  • Peptide and polypeptide toxins are also useful as active moieties, and the present disclosure specifically contemplates embodiments wherein the antibodies, antigen binding portions, and peptides are coupled to a toxin.
  • the antibodies, antigen binding portions, or peptides and the toxin are both polypeptides and are provided in the form of a fusion protein.
  • Peptide and polypeptide toxins are generally complex toxic products of various organisms including bacteria, plants, etc.
  • toxins include but are not limited to: ricin, ricin A chain (ricin toxin), Pseudomonas exotoxin (PE), diphtheria toxin (DT), Clostridium perfringens phospholipase C (PLC), bovine pancreatic ribonuclease (BPR), pokeweed antiviral protein (PAP), abrin, abrin A chain (abrin toxin), cobra venom factor (CVF), gelonin (GEL), saporin (SAP), modeccin, viscumin and volkensin.
  • ricin ricin A chain
  • PE Pseudomonas exotoxin
  • DT diphtheria toxin
  • PLC Clostridium perfringens phospholipase C
  • BPR bovine pancreatic ribonuclease
  • PAP pokeweed antiviral protein
  • abrin abrin
  • abrin A chain abrin A
  • Chemotherapeutic agents include chemotherapeutic drugs that are commercially available.
  • the chemotherapeutic can be an inhibitor of chromatin function, a topoisomerase inhibitor, a microtubule inhibiting drug, a DNA damaging agent, an antimetabolite (such as folate antagonists, pyrimidine analogs, purine analogs, and sugar-modified analogs), a DNA synthesis inhibitor, a DNA interactive agent (such as an intercalating agent), and/or a DNA repair inhibitor.
  • a DNA damaging agent such as folate antagonists, pyrimidine analogs, purine analogs, and sugar-modified analogs
  • an antimetabolite such as folate antagonists, pyrimidine analogs, purine analogs, and sugar-modified analogs
  • a DNA synthesis inhibitor such as an intercalating agent
  • a DNA interactive agent such as an intercalating agent
  • Chemotherapeutic agents may be categorized by their mechanism of action into, for example, the following groups: anti-metabolites/anti-cancer agents, such as pyrimidine analogs (5-fluorouracil, floxuridine, capecitabine, gemcitabine and cytarabine) and purine analogs, folate antagonists and related inhibitors (mercaptopurine, thioguanine, pentostatin and 2-chlorodeoxyadenosine (cladribine)); antiproliferative/antimitotic agents including natural products such as vinca alkaloids (vinblastine, vincristine, and vinorelbine), microtubule disruptors such as taxane (paclitaxel, docetaxel), vincristin, vinblastin, nocodazole, epothilones and navelbine, epidipodophyllotoxins (etoposide, teniposide), DNA damaging agents (actinomycin, amsacrine, anthracyclines,
  • an antibody or antigen-binding portion thereof as described herein may comprise one or more amino acid analogs, derivatives and congeners of any specific amino acid referred to herein, as well as C-terminal or N-terminal protected amino acid derivatives (e.g. modified with an N-terminal or C-terminal protecting group).
  • amino acid analogs, derivatives and congeners of any specific amino acid referred to herein as well as C-terminal or N-terminal protected amino acid derivatives (e.g. modified with an N-terminal or C-terminal protecting group).
  • one may use an amino acid analog wherein a side chain is lengthened or shortened while still providing a carboxyl, amino or other reactive precursor functional group for cyclization, as well as amino acid analogs having variant side chains with appropriate functional groups).
  • the subject compound can include an amino acid analog such as, for example, cyanoalanine, canavanine, djenkolic acid, norleucine, 3-phosphoserine, homoserine, dihydroxy-phenylalanine, 5-hydroxytryptophan, 1-methylhistidine, 3-methylhistidine, diaminopimelic acid, ornithine, or diaminobutyric acid.
  • amino acid analog such as, for example, cyanoalanine, canavanine, djenkolic acid, norleucine, 3-phosphoserine, homoserine, dihydroxy-phenylalanine, 5-hydroxytryptophan, 1-methylhistidine, 3-methylhistidine, diaminopimelic acid, ornithine, or diaminobutyric acid.
  • amino acid analog such as, for example, cyanoalanine, canavanine, djenkolic acid, norleucine, 3-phosphoserine, homoserine, dihydroxy-phenylalanine
  • the antibodies and antigen-binding portions thereof may be co-administered with antibodies immunoreactive with the vasopressin abnormal V2 receptor. Due to a splicing error, cancer cells often produce an abnormal form of the V2 receptor, which is a good tumor cell marker for targeted therapy.
  • the antagonists are formulated with a pharmaceutically acceptable carrier.
  • the antibodies or antibody variants can be administered alone or as a component of a pharmaceutical formulation (composition). They may be formulated for administration in any convenient way for use in human or veterinary medicine. Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.
  • the subject formulations include those suitable for oral, dietary, topical, parenteral (e.g., intravenous, intraarterial, intramuscular, subcutaneous injection), inhalation (e.g., intrabronchial, intranasal or oral inhalation, intranasal drops), rectal, and/or intravaginal administration.
  • parenteral e.g., intravenous, intraarterial, intramuscular, subcutaneous injection
  • inhalation e.g., intrabronchial, intranasal or oral inhalation, intranasal drops
  • rectal e.g., rectal, and/or intravaginal administration.
  • Other suitable methods of administration can also include rechargeable or biodegradable devices and slow release devices such as slow release polymeric devices.
  • the pharmaceutical compositions can also be administered as part of a combinatorial therapy with other agents (either in the same formulation or in a separate formulation).
  • the formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy.
  • the amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, the particular mode of administration.
  • the amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect.
  • methods of preparing these formulations or compositions include combining another type of anti-cancer therapeutic agent and a carrier and, optionally, one or more accessory ingredients.
  • the formulations can be prepared with a liquid carrier, or a finely divided solid carrier, or both, and then, if necessary, shaping the product.
  • compositions suitable for parenteral administration may comprise one or more antibodies, antigen-binding portions thereof, or peptides in combination with one or more pharmaceutically acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
  • aqueous and nonaqueous carriers examples include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate.
  • polyols such as glycerol, propylene glycol, polyethylene glycol, and the like
  • vegetable oils such as olive oil
  • injectable organic esters such as ethyl oleate.
  • Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
  • compositions may also contain adjuvants, such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption, such as aluminum monostearate and gelatin.
  • adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents.
  • Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium
  • the antibodies or antigen-binding portions are formulated with pharmaceutically acceptable carriers.
  • materials which may serve as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents,
  • Injectable depot forms are made by forming microencapsule matrices of one or more antibodies in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of drug to polymer, and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes, polymeric nanoparticles, or microemulsions which are compatible with body tissue.
  • biodegradable polymers such as polylactide-polyglycolide.
  • Depot injectable formulations are also prepared by entrapping the drug in liposomes, polymeric nanoparticles, or microemulsions which are compatible with body tissue.
  • the pharmaceutical composition is administered by subcutaneous, intravenous, intranasal, parenteral, transdermal, intracheal, intravenous, intramuscular, intracranial, intrathecal or intravitreal injection; by oral administration, eye drops, pessary, or inhalation.
  • the antibodies, antigen-binding portions thereof, or peptides can be administered in a variety of unit dosage forms.
  • the dose will vary according to the particular antibody or antigen-binding portion thereof.
  • different antibodies may have different masses and/or affinities, and thus require different dosage levels.
  • Antibodies prepared as Fab′ fragments will also require differing dosages than the equivalent intact immunoglobulins, as they are of considerably smaller mass than intact immunoglobulins, and thus require lower dosages to reach the same molar levels in the patient's blood.
  • Dosage levels of the antibodies for human subjects are generally between about 1 mg per kg and about 100 mg per kg per patient per treatment, and preferably between about 5 mg per kg and about 50 mg per kg per patient per treatment.
  • the antibody concentrations are preferably in the range from about 5-1000 ⁇ g/ml, preferably 25 ⁇ g/ml to about 500 ⁇ g/ml.
  • a typical therapeutic treatment includes a series of doses, which will usually be administered concurrently with the monitoring of clinical endpoints (such as tumor load or presence of provasopressin fragments in the bloodstream) with the dosage levels adjusted as needed to achieve the desired clinical outcome.
  • clinical endpoints such as tumor load or presence of provasopressin fragments in the bloodstream
  • Other protocols can, of course, be used if desired as determined by the physician.
  • compositions described herein may be performed by an intravascular route, e.g., via intravenous infusion by injection.
  • Other routes of administration may be used if desired, such as s.c. injection.
  • Formulations suitable for injection are found in Remington's Pharmaceutical Sciences, Mack Publishing Company, Philadelphia, Pa., 17th ed. (1985).
  • Such formulations must be sterile and non-pyrogenic, and generally will include a pharmaceutically effective carrier, such as saline, buffered (e.g., phosphate buffered) saline, Hank's solution, Ringer's solution, dextrose/saline, glucose solutions, and the like.
  • the formulations may contain pharmaceutically acceptable auxiliary substances as required, such as, tonicity adjusting agents, wetting agents, bactericidal agents, preservatives, stabilizers, etc.
  • Applicants provide, inter alia, a rapid, inexpensive, sensitive, and specific method for: 1) early detection of cancer; and 2) identifying and localizing provasopressin-expressing cancers, including metastatic and/or recurrent disease, in patients.
  • Cancers that may be imaged using the methods herein include carcinoid tumors and pancreatic endocrine tumors, and others discussed in section 7 of this application.
  • Detection kits are simple enough to be set up in any local hospital laboratory, and anti-provasopressin antibodies and antigen-binding portions thereof can readily be made available to all hospitals treating patients with breast cancer.
  • the instant disclosure also provides a method of phenotyping biological samples from patients having a provasopressin-expressing cancer other than breast cancer or small cell lung cancer comprising: (a) obtaining a biological sample from a patient; (b) (optionally) rendering the biological sample amenable to immunoassay; (c) contacting the rendered sample with the a provasopressin-binding antibody or antigen-binding portion thereof under conditions that allow for binding of the antibody or antigen-binding portion to provasopressin; and (d) determining if the cells of the rendered sample inappropriately express provasopressin compared to a control tissue; wherein if the test tissue inappropriately expresses provasopressin, the biological sample is identified as likely having cancerous cells.
  • test tissue shows inappropriate provasopressin expression
  • the patient before step (a), the patient has been diagnosed as having a provasopressin-expressing cancer such as prostate cancer, pancreatic cancer, or neuroendocrine cancer.
  • Certain tumors may be detected by measuring blood levels of provasopressin components. This may be done with anti-provasopressin antibodies, antigen-binding portions thereof. Such antibodies include, for example, MAG-1, MAG-2, MAG-3, MAG-4, and MAG-5, and any of the derivative antibodies and antigen-binding portions thereof referred to herein. These antibodies and antigen-binding portions thereof would be useful in the clinical screening assay to measure provasopressin (or fragments of provasopressin) levels in the blood of patients suspected of having provasopressin-expressing tumors (such as neuroendocrine, pancreatic, or prostate tumors), or who have had those tumors in the past. This would be a useful, non-invasive or less invasive test to possibly justify further, more invasive tests/biopsies, and aid in monitoring recurrence of disease.
  • Applicants disclose, among other things, a method of detecting a tumor in a patient having a provasopressin-expressing cancer other than breast cancer or small cell lung cancer comprising: (a) administering a pharmaceutical composition comprising a provasopressin-binding antibody or antigen-binding portion thereof to the patient, (b) detecting the label, and (c) determining if the patient has cells that inappropriately express provasopressin compared to a control; wherein if the patient has cells that inappropriately express provasopressin, the patient is identified as likely having a tumor.
  • the method further comprises, if the patient has cells that inappropriately express provasopressin, administering a therapeutically effective amount of a provasopressin-binding antibody or antigen-binding portion thereof to the patient.
  • the patient before step (a), the patient has been diagnosed as having a provasopressin-expressing cancer.
  • the method may further comprise determining the location and/or volume of a plurality cells inappropriately expressing provasopressin (for example, determining the volume of a tumor). This method may be used to determine the location of a tumor prior to surgical resection of the tumor. It may also be used to determine whether surgery is appropriate.
  • antagonists e.g., antibodies directed against various portions NRSA/GRSA
  • current imaging techniques such as MRI
  • new imaging protocols for diseases such as pancreatic and prostate cancer could be developed and effectively implemented for clinical use.
  • These types of techniques would be especially useful for the detection of metastatic disease.
  • These techniques could also assist a surgeon preparing to surgically remove a tumor or tumors, by identifying the location of the tumor or tumors.
  • Applicants disclose, inter alia, a method of treating a provasopressin-expressing cancer, comprising administering an effective amount of the pharmaceutical compositions described herein to a subject.
  • These pharmaceutical compositions include anti-provasopressin antibodies (such as MAG-1, MAG-2, MAG-3, MAG-4, and MAG-5 or any of the variants described herein), and antigen-binding portions thereof.
  • an antibody (or antigen-binding portion thereof) suitable for therapeutic use is a humanized antibody or antigen-binding portion thereof.
  • the antibodies and antigen-binding portions may be humanized by any means known in the art, such as CDR grafting or generation of a chimeric antibody. Specific point mutations may also be made during the humanization process.
  • Antibodies can be used for targeting provasopressin (NRSA/GRSA) on certain tumors. It was shown previously that SCLC tumors can be localized and imaged in humans using radiolabeled antibody directed against the neurophysin portion of provasopressin. Subsequent studies show that polyclonal antibodies, monoclonal antibodies, and antibody Fab fragments directed against different regions of the provasopressin protein bind specifically to cultured SCLC and breast cancer cells, as well as to human tumor sections, but not to tissue that is devoid of tumor.
  • NRSA/GRSA Described herein are polyclonal and monoclonal antibodies, and their Fab fragment derivatives, to NRSA/GRSA. It has been shown here that these antibodies and fragments can bind to cultured human cancer cells and human cancer tissue other than that of SCLC and breast cancer. Since the NRSA/GRSA is not typically found in normal cells, it can serve as an excellent target for tumor localization in the early detection, diagnosis, and treatment of cancers that express the vasopressin gene. NRSA/GRSA also provides for a attractive candidate for use in vaccine development strategies for the prevention of those cancers that express the vasopressin gene.
  • Single-chain antibodies fragments and small binding peptides can be used for targeting provasopressin (NRSA/GRSA) on tumors.
  • NRSA/GRSA provasopressin
  • scFv single-chain variable region fragments
  • An effective therapeutic response is achieved when the patient experiences partial or total alleviation or reduction of signs or symptoms of illness, and specifically includes, without limitation, prolongation of survival.
  • a therapeutic response is achieved when the patient's symptoms remain static, and the tumor burden does not increase.
  • Applicants disclose, inter alia, a method of treating provasopressin-expressing cancers, comprising administering an effective amount of a pharmaceutical composition comprising an anti-provasopressin antibody (such as MAG-1, MAG-2, MAG-3, MAG-4, and MAG-5 or any of the variants described herein), or an antigen-binding portion thereof to a subject, and further comprising administration of a second treatment.
  • the second treatment may be surgery, radiation therapy, or an effective amount of a second pharmaceutical composition.
  • the second pharmaceutical compositions may comprise a chemotherapeutic agent, and optionally comprising epinephrine.
  • the pharmaceutical compositions may be administered concomitantly, in a single formulation, or in separate formulations.
  • the second pharmaceutical composition may comprise one or more of dexamethasone, IBMX, and 8-bromoadenosine 3′,5′-cyclic monophosphate (8br-cAMP).
  • the second pharmaceutical composition comprises each of dexamethasone, IBMX, and 8-bromoadenosine 3′,5′-cyclic monophosphate (8br-cAMP).
  • the second pharmaceutical composition may comprise one or more of IBMX and forskolin.
  • the second pharmaceutical composition comprises both of IBMX and forskolin.
  • Provasopressin-binding antibodies and antigen binding portions can be used in combination therapy with chemotherapeutic agents. As described herein, provasopressin-binding antibodies and antigen-binding portions thereof in combination with a cocktail of chemotherapeutic agents are effective at inhibiting proliferation of cancerous cells when administered in an effective amount.
  • Treatment for the various representative cancers including chemotherapy using chemnotherapeutic agents, are described in more detail below for the representative cancers. All such treatments may be used in combination with treatment with the subject provasopressin-binding agents.
  • provasopressin-expressing cancer examples include neuroendocrine cancers, prostate cancer, and pancreatic cancer.
  • the provasopressin-expressing cancer is not SCLC and breast cancer.
  • neuroendocrine tumors are either carcinoid tumors or pancreatic endocrine tumors (PETs).
  • the neuroendocrine tumor is a pancreatic tumor that is not an adenopancreatic cancer or exocrine pancreatic cancer.
  • a neuroendocrine tumor may be, for example, an insulinoma, a gastrinoma, a glucagonoma, a VIPoma, a PPoma, a somatostatinoma, a CHRoma, a calcitoninoma, a GHRHoma, a neurotensinoma, a ACTHoma, a GRFoma, a GRFoma, a parathyroid hormone-related peptide tumor, or a WDHA.
  • Carcinoid tumors may arise from several points of origin, including the foregut (lung, thymus, stomach, and duodenum), midgut (distal ileum and proximal colon), or hindgut (distal colon and rectum). Some carcinoid tumors produce serotonin.
  • Neuroendocrine cancers may be brain, gastroenteric, ovarian, testicular, adrenal, or skin cancers.
  • Certain methods of diagnosing neuroendocrine cancers are known in the art. For example, MRI, blood tests to determine hormone levels, CT scans, sonography, and endoscopy may be used to diagnose neuroendocrine cancers. Also, a number of biomarkers for neuroendocrine cancers are known, including chromogranin A, urine 5-hydroxy indole acetic acid, neuron-specific enolase, and synaptophysin. The diagnostic techniques provided herein may be used in concert with any other technique for diagnosing neuroendocrine cancer.
  • somatostatin analogues such as octreotide (marketed as Sandostatin).
  • the somatostatin analogue is conjugated to a radionuclide such as indium-111, lutetium-177, or yttrium-90.
  • Chemotherapy, surgery, and radiation therapy may also be used to treat neuroendocrine cancers.
  • a chemotherapeutic agent is delivered to the hepatic artery to target neuroendocrine tumors in the liver. Radiofrequency ablation and cryoablation are other techniques used in the therapy of neuroendocrine cancers.
  • neovascularization inhibitors include epidermal growth factor receptor (EGFR) inhibitors, vascular endothelial growth factor receptors (VEGFR) inhibitors, and angiopoietin-related growth factor (AGF) inhibitors.
  • Treatments of neuroendocrine cancers include interferons, cisplatin, etoposide, doxorubicin, streptozocin, everolimus (Afinitor), imatinib, sunitinib (Sutent), temozolide, thalidomide, sorafenib, and panitumumab.
  • Treatment with a provasopressin-binding antibody or antigen-binding portion thereof may be combined with any of the above therapies.
  • Pancreatic cancer includes pancreatic carcinomas, sarcomas, and melanomas. These may occur in poorly differentiated, moderately differentiated, and well differentiated forms. Some pancreatic cancers are neuroendocrine cancers. Others are adenopancreatic cancers. Pancreatic cancers include endocrine and exocrine pancreatic cancer. Pancreatic tumors can be benign or malignant.
  • pancreatic cancers A number of methods of diagnosing pancreatic cancers are known in the art. For example, a patient may present with one or more of pain, jaundice, weight loss, loss of appetite. Imagine techniques such as CT scans, MRI, and endoscopic ultrasound can be used to identify a pancreatic tumor. The diagnostic techniques provided herein may be used in concert with any other technique for diagnosing pancreatic cancer.
  • chemotherapeutic agents include gemcitabine (Gemcitabine Hydrochloride), Gemzar (Gemcitabine Hydrochloride), oxaliplatin, Fluorouracil (5FU), Adrucil (Fluorouracil), Efudex (Fluorouracil), Fluoroplex (Fluorouracil), Mitomycin C, Mitozytrex (Mitomycin C), Mutamycin (Mitomycin C), or Erlotinib Hydrochloride (Tarceva).
  • pancreatic cancer Another treatment for pancreatic cancer is the monoclonal antibody Denosumab.
  • the therapeutic techniques provided herein may be used in concert with any other technique for treating pancreatic cancer.
  • Prostate cancer Types of prostate cancer include neuroendocrine prostate cancer, sarcomas, small cell carcinomas, transitional cell carcinomas, and prostate adenocarcinomas.
  • Prostate cancer may be classified into four stages, T1, T2, T3, and T4.
  • Prostate tumors can be benign or malignant.
  • Prostate cancer can be identified by screening for elevated levels of PSA. Diagnosis can also involve imaging techniques such as transrectal ultrasound. Biopsies, such as needle biopsies, are another common diagnostic technique. The diagnostic techniques provided herein may be used in concert with any other technique for diagnosing prostate cancer.
  • Prostate cancer can be treated by, for example, surgery, radiation therapy, cancer vaccines, proton therapy, cryotherapy, hormonal therapy, high intensity focused ultrasound, proton beam radiation therapy, and chemotherapy.
  • Androgen ablation is a common treatment, and can involve surgical removal of the testicles, administration of female sex hormones, and treatment with antiandrogens (such as finasteride).
  • Chemotherapeutic agents used to treat prostate cancer include docetaxel (Taxotere), doxorubicin (Adriamycin), estramustine phosphate (Emcyt), etoposide (Vepsid), mitoxantrone (Novantrone), paclitaxel (Taxol), vinblastine (Velban), Cabazitaxel, Degarelix, Docetaxel, Enzalutamide Jevtana (Cabazitaxel), Leuprolide Acetate, Lupron (Leuprolide Acetate), Lupron Depot (Leuprolide Acetate), Lupron Depot-3 Month (Leuprolide Acetate), Lupron Depot-4 Month (Leuprolide Acetate), Lupron Depot-Ped (Leuprolide Acetate), Prednisone, Provenge (Sipuleucel-T), Sipuleucel-T, Taxotere (Docetaxel), Viadur (Leuprolide Acetate),
  • the therapeutic techniques provided herein may be used in concert with any other technique for treating prostate cancer.
  • kits useful for screening a biological sample for a provasopressin-expressing cancer and for identifying/selecting patients (form which the sample is derived from) for treatment comprising a preparation of an antibody or antigen binding portion immunoreactive with provasopressin or fragment of provasopressin, wherein the antibody immunoreactive with provasopressin indicates the presence of a provasopressin-expressing cancer.
  • the kit may be labeled for use in detecting provasopressin-expressing tumors.
  • the fragment of provasopressin may be, for example, SEQ ID NOs: 1, 5, or 6. If the biological sample is positive for provasopressin, a provasopressin-expressing cancer has been identified.
  • kits include preparations of antibodies or antigen binding portions immunoreactive with provasopressin or fragment of provasopressin.
  • Antibodies and antigen binding portions can be lyophilized or in solution. Additionally, the preparations can contain stabilizers to increase the shelf-life of the kits, e.g., bovine serum albumin (BSA). Wherein the antibodies and antigen binding portions are lyophilized, the kit can contain further preparations of solutions to reconstitute the preparations. Acceptable solutions are well known in the art, e.g., PBS.
  • Kits can further include the components for an ELISA assay for measuring provasopressin and fragments thereof as tumor markers in body fluids.
  • Samples to be tested in this application include, for example, plasma, urine, lymph, breast ductal secretions and products thereof.
  • preparations of the kits may be used in immunoassays, such as immunohistochemistry to test patient tissue biopsy sections.
  • compositions of the kit can be formulated in single or multiple units for either a single test or multiple tests.
  • preparations of the kit are free of pyrogens.
  • kits can include instructions for the use of the compositions in an immunoassay.
  • Cultured cells were grown in DMEM/F12 (50:50) medium supplemented with 10% Fetal calf serum, 2 mM glutamine, 100 units/mL penicillin and 100 ⁇ g/mL streptomycin at 37° C. and 5% CO 2 .
  • Table 1 is a list of representative cancer cell lines used for the studies. These cells are available at American Type Culture Collection (ATCC) (Manassas, Va.). Human normal and tumor tissue samples were obtained commercially or from the Pathology Department of Dartmouth Medical School. Human hypothalamus tissue was obtained at autopsy with the assistance of Dr. C. Harker Rhodes (Dartmouth Medical School).
  • ATCC American Type Culture Collection
  • MAG-1 mAb was generated against a synthetic 18-amino acid peptide representing the COOH-terminal VAG region of the pro-VP protein (VAGcl8: VQLAGAPEPFEPAQPDAY; SEQ ID NO: 5) coupled to bovine thyroglobulin using glutaraldehyde.
  • This complex was used as a 1 mg/mL solution (peptide equivalent concentration) in 0.05 M sodium phosphate (pH 7.0) that had been sonicated with an equal volume of complete Fruend's adjuvant (CFA) to immunize BALB/c mice.
  • CFA Fruend's adjuvant
  • a follow-up immunization was performed 21 days later using an mixture of antigen with incomplete Freund's adjuvant (IFA), and spleen cells were harvested after an additional five days.
  • the spleen cells were hybridized with Sp2/0-Ag14 cells, and viable hybridomas were selected using DMEM containing 10% FBS and supplemented with hypoxanthine-aminopterin-thymidine (HAT) (Sigma). Clones were screened for the production of antibodies using 125 I -VAGcl8 peptide by displacement RIA (North et al. (1978) Endocrinology, 103: 1976-1984). The MAG-1-producing clone was isolated, used to generate MAG-1 monoclonal antibody, which was purified by a Protein A column.
  • HAT hypoxanthine-aminopterin-thymidine
  • MAG-1 was determined to be of isotype IgG 1 using a Clonotyping System kit (Southern Biotechnology Associates, Birmingham, Ala.). Fab fragments of MAG-1 were generated using an ImmunoPure IgG 1 Fab and F(ab) 2 Preparation Kit (Pierce, Rockford, Ill.) following the manufacturer's instructions, and complete ficin digestion of the IgG molecule was confirmed by Western analysis.
  • Chimeric and humanized MAG-1 antibody were generated after the cloning of the heavy and light chain of the murine MAG-1 antibody by conventional means as described in the literature. Both chimeric and humanized MAG-1 were cloned and expressed in Chinese Hamster Cells (CHO).
  • This or similar procedures may be used (optionally with minor modifications) to produce other antibodies with similar binding property as that of MAG-1.
  • four additional similar antibodies (MAG-2, -3, -4, and -5) were produced using similar procedures. See Example 1 of WO2009/137113A2 (incorporated by reference).
  • the hybridomas used to produce MAG-1 to MAG-5 are 8D12A4, 8D12A12, 4E5A5, 4E5A11, AND 8C10A11, respectively.
  • These monoclonal antibodies all bind to the VAGcl8 antigen used to raise the antibodies, but all fail to bind to a related peptide produced by replacing the 9 th Pro in the VAGcl8 sequence with His.
  • the MAG-1 related antibodies all behave similarly in competitive inhibition binding studies, and their K d are all within 10-fold of one another (e.g., for MAG-1 to MAG-5, 1.5 ⁇ 10 ⁇ 8 M, 1.5 ⁇ 10 ⁇ 8 M, 2.7 ⁇ 10 ⁇ 8 M, 3.25 ⁇ 10 ⁇ 9 M, and 3.41 ⁇ 10 ⁇ 9 M, respectively, concerning binding to the VAGcl8 antigen), demonstrating the reliability of the antibody production method. See WO2009/137113A2 (incorporated by reference) for further characterization.
  • RT-PCR Reverse-Transcriptase Polymerase Chain Reaction
  • PCR Polymerase chain reaction
  • AVPfwd (5′-aggatgcctgacaccatgctg-3′; SEQ ID NO: 8) and AVPrev (5′-attggcggaggtttattgtc-3′; SEQ ID NO: 9) in a reaction employing MasterTaq enzyme, TagMaster PCR Enhancer buffer, and a Mastercycler Gradient thermocycler (Eppendorf, Westbury, N.Y.).
  • MasterTaq enzyme TagMaster PCR Enhancer buffer
  • a Mastercycler Gradient thermocycler Eppendorf, Westbury, N.Y.
  • Cycle conditions were as follows: 1 ⁇ (95° C. for 5 min), 4 ⁇ (95° C. for 1 min, 62° C. for 1 min minus 1° C. per cycle, 72° C. for 1 min), 30 ⁇ (95° C. for 1 min, 57° C. for 1 min, 72° C. for 1 min) followed by a final extension at 72° C. for 10 min
  • RT-PCR Reverse-Transcriptase Polymerase Chain Reaction
  • PCR Polymerase chain reaction
  • Vh fwd (5′-AGGTSMARCTGCAGSAGTCWGG-3′; SEQ ID NO: 14);
  • Vh rev (5′-CCAGGGGCCAGTGGATAGACAAGCTTGGGTGTCGTTTT-3′; SEQ ID NO: 15);
  • Vl fwd (5′-GGTGATATCWTGMTGACCCAAWCTCCACTCTC-3′; SEQ ID NO: 16);
  • Vl rev (5′-GGGAAGATGGATCCAGTTGGTGCAGCATCAGC-3′; SEQ ID NO: 17); in a reaction employing MasterTaq enzyme, TagMaster PCR Enhancer buffer, and a Mastercycler Gradient thermocycler (Eppendorf, Westbury, N.Y.).
  • Vh-fwd (5′-GGGCCCAGGCGGCCGAGGTCAAGCTGCAGGAGTCA-3′; SEQ ID NO: 18); Vl-rev: (5′-CCTGGCCGGCCTGGCCTTTKATTTCCAGYTTGGTCCC-3′; SEQ ID NO: 19); Vh rev: (5′-ACCGGAAGTAGAGCCGGAGACTGTGAGAGTGGAGCC-3′; SEQ ID NO: 20); and Vl fwd: (5′-GGCTCTACTTCCGGTGATATCGTTATGACCCCAACT-3′; SEQ ID NO: 21).
  • PCR conditions were as follows: initial denaturation of 94° C. for 5 minutes; 35 cycles (30 sec at 90° C., 30 sec at 52° C.
  • Vl-fwd (5′-GGGCCCAGGCGGCCGAGCTCGAYATCCAGCTGACTCAGCC-3′; SEQ ID NO: 10); Vh-rev: (5′-CCTGGCCGGCCTGGCCACTAGTGACAGATGGGGSTGTYGTTTTGG-3′; SEQ ID NO: 11); Vl-rev: (5′-GGAAGATCTAGAGGAACCACCTTTKATTTCCAGYTTGGTCCC-3′; SEQ ID NO: 12); and Vh-fwd: (5′-GGTGGTTCCTCTAGATCTTCCCTCGAGGTR MAGCTTCAGGAGTC-3′; SEQ ID NO: 13).
  • PCR conditions were as follows: initial denaturation of 94° C. for 5 minutes; 35 cycles (30 sec at 90° C., 30 sec at 56° C., 90 sec at 72° C.); followed by a final extension at 72° C. for 10 minutes.
  • the fluid was aspirated and 50 ⁇ l of MAG-1, the primary antibody at a concentration of 10 ⁇ g/ml were then added to the cells and incubated at room temperature for an hour.
  • the cells were then washed thrice with PBS.
  • 50 ⁇ L of goat anti-mouse Fab-FITC at a 1:2000 dilution were added and incubated at room temperature for 1 hr.
  • the stained cells were then visualized by confocal microscopy, using a confocal microscope.
  • chimeric or humanized MAG-1 was used for staining as the primary antibody, goat anti-human heavy and light chain was used as at the secondary antibody.
  • MOPC-21 was used as the primary antibody.
  • the MAG-1 was incubated with the C18 peptide used to raise the monoclonal antibody before adding to the cancer cells on the cover slip.
  • Sections of 4-6 ⁇ m from each formalin-fixed, or acetone-fixed, paraffin-embedded specimens of human SCLC, normal lung, or hypothalamus tissue were stained for NRSA with MAG-1 mAb.
  • Fixed preparations of breast cancer, DCIS, fibrocystic disease, or normal breast tissue were stained for GRSA with MAG-1. All steps were performed at ambient temperature unless otherwise stated.
  • the sections were de-paraffinized by heat exposure (60° C. for 2 h) followed by xylene washes (2 ⁇ 10 min), and tissues were re-hydrated by washes (10 min) in descending concentrations of ethanol (100%-70%).
  • Endogenous peroxide activity was blocked by incubation in 0.6% hydrogen peroxidase in methanol for 10 min After washing with PBS (2 ⁇ 3 min), the tissues were subjected to antigen retrieval by proteolytic digestion with trypsin solution (BioGenex, San Ramon, Calif.) for 10 min at 37° C., washed in 95% ethanol for one minute, and then in PBS for 10 min Slides were blocked with Power Block Universal Blocking Reagent (BioGenex) for 20 min and incubated with MAG-1 mAb (0.25 ⁇ g/ml) in PBS with 0.1% BSA overnight at 4° C.
  • trypsin solution BioGenex, San Ramon, Calif.
  • sections of 4-6 ⁇ m from each formalin-fixed paraffin-embedded specimens of human SCLC, normal lung, or hypothalamus tissue were stained for NRSA with MAG-1 mAb. All steps were performed at ambient temperature unless otherwise stated.
  • the sections were deparaffinized by heat exposure to (60° C. for 10 min) followed by xylene washes (2 ⁇ 5 min), and tissues were re-hydrated by washes (2 ⁇ 5 min) in descending concentrations of ethanol (100%, 95%, and 70%). After washing with PBS (2 ⁇ 5 min), the tissues were subjected to antigen retrieval by 0.01 M sodium citrate (pH 8.5) for 30 min at 80° C.
  • the PCR reaction was carried out with sequence-specific primers that spanned the two introns of the vasopressin gene.
  • RNA extracted from the SCLC tumor, SCLC cultured cells, and human hypothalamus tissue FIG. 1 .
  • This band corresponds in size to that predicted (570 bp) for the VP message employing these particular amplification primers.
  • There was no VP message detected in total RNA extract from the Beas-2B cells while there was a faint band at ⁇ 570 bp detected in the non-tumor lung tissue extract. It is possible that this represents VP expression by small, undetected SCLC tumor cells embedded in the lung tissue sample, or expression by pulmonary neuroendocrine cells (Reynolds (2000) Am. J. Physiol. Lung Cell. Mol. Physiol. 278: L1256-L1263).
  • FIG. 2A When cultured SCLC cell protein extract was examined using a polyclonal antibody raised against VP-NP (North, Peptides 14: 303-307, 1993), a banding pattern identical to that produced using the MAG-1 mAb was observed ( FIG. 2B ).
  • the MAG-1 mAb and Fab, as well as the polyclonal anti-VP-NP antibody recognize proteins with molecular masses of ⁇ 20 and ⁇ 40 kDa, along with what appear to be degradation products and/or deglycosylated forms of the pro-VP protein.
  • the ⁇ 20 kDa protein corresponds to the expected size for the pro-VP protein.
  • NCI-H82 cells were reacted with MAG-1 mAb or Fab, followed by FITC-labeled goat anti-mouse Fab-specific antibody, and fluorescence was measured on a FACStar apparatus ( FIG. 3 ).
  • a similar level of staining was observed using a 1 ⁇ g/mL concentration of MAG-1 mAb or Fab, however the mean fluorescence measured was increased only ⁇ 2-fold when the concentration of Fab was used at 100 ⁇ g/ml, whereas it increased ⁇ 10-fold when using the mAb at that concentration. Since reactions were performed at 4° C.
  • the MAG-1 mAb has a higher binding capacity than MAG-1 Fab for NRSA on the surface of cultured SCLC cells.
  • the mAb was also used to detect NRSA on the surface of Lu-165 and NCI-H345 cultured SCLC cells. The intensity of the fluorescence measured after staining with the isotype control mouse mAb was equivalent to that measured in unstained cells. The binding of the MAG-1 mAb to NRSA on the surface of cultured SCLC cells was also assessed by fluorescent microscopy.
  • FIG. 4 a non-uniform pattern of staining of the cell surface was observed on SCLC cells while almost no staining was present when the isotype control antibody was used.
  • Propidium iodide was used to stain the nuclei of the NCI-H82 cells for contrast, after the cells had been incubated with MAG-1, FITC-conjugated anti-mouse antibody, and fixed paraformaldehyde ( FIG. 4A ).
  • FIGS. 4B and 4C punctuate plasma membrane staining was observed. While a quantitative assessment concerning the percentage of cells that were found to be immunoreactive with MAG-1 was not made, it is clear that there was a varied level of labeling of individual cells within the population of each cell type.
  • MAG-1 can detect abnormal provasopressin expression on SCLC and breast cancer cells. This example provides evidence that abnormal provasopressin expression is also identified in virtually all cancer tissues examined, especially in tissues from ovarian cancer, prostate cancer, and neuroendocrine cancer.
  • Applicants have so-far performed IHC on 22 cases of invasive ovarian cancer represented by tissue arrays and tissue sections. These studies revealed a positive staining with MAG-1, and therefore the presence of GRSA in seemingly all neoplastic cells of all tumor tissue sections. In contrast, no staining was found with samples from normal human ovary, kidney, breast, liver, lung, and 28 other normal human tissues. See FIG. 8 , showing a representative IHC staining result with MAG-1 on sections of three ovarian cancers (OC1, OC2, and OC3).
  • Table 2 below provides a list of cancers tested positive for provasopressin overexpression.
  • Applicants have also performed IHC on 22 cases of prostate cancer represented by tissue arrays and tissue sections. As with ovarian cancer, these prostate cancer samples all gave positive IHC staining with MAG-1, showing the common expression of the GRSA surface marker by these tumors. Again, in contrast, there was no observed reaction of MAG-1 with normal prostate tissues ( FIG. 9 ).
  • ovarian cancer cell lines were tested in this example: A2780, A2008, and SK-OV3 cells.
  • Cell surface expression of GRSA was demonstrated both by Western analysis and by confocal microscopy employing MAG-1 (see below).
  • FIG. 10 shows confocal image of surface fluorescent staining of GRSA on ovarian cancer cells A2780 and SK-OV3.
  • FIG. 13 for confocal images showing cell surface localization of the GRSA antigen in ovarian cancer cell lines SKOV3 and OV2008.
  • LNCAP cells Two prostate cancer cell lines were tested in this example: LNCAP cells and PC3 cells. Again, cell surface expression of GRSA was demonstrated both by Western analysis and by confocal microscopy employing MAG-1 (see below).
  • FIG. 11 shows confocal image of surface fluorescent staining of GRSA on LNCAP prostate cancer cells.
  • FIG. 13 for confocal images showing cell surface localization of the GRSA antigen in prostate cancer cell line PC3.
  • FIG. 13 further shows the same cell surface localization for the GRSA antigen in pancreatic cancer cell lines bxpc3 and panc1.
  • MAG-1 antibody and other agents that target the GRSA surface antigen can be used for the identification/diagnosis/treatment of tumors in provasopressin-expressing cancer cells, such as ovarian, prostate, and endometrial tissues.
  • These agents can serve, either in their natural form or in their modified forms, or in combination with radiation or chemotherapeutics, as targeting therapeutic agents for these disease states.
  • amino acid sequences of the heavy and light chains of the mature protein, at the amino terminal regions, were determined by protein sequencing after isolating the reduced and s-alkylated heavy and light chains by SDS polyacrylamide gel electrophoresis.
  • amino terminal regions of the heavy and light chains obtained by protein sequencing are summarized below.
  • CHO Chinese Hamster Ovary
  • Applicants first identified several human framework regions which have at least 70% homology with the mouse framework regions of MAG-1. Applicants then designed three sets of heavy and light chain variable regions based on the human framework sequences and certain amino acid substitutions using computer modeling. Applicants screened all the expressed constructs, then selected and produced a sufficient quantities of a H2L2 (hMAG-1) construct by transient expression in HEK 293 cells for further analysis. The hMAG-1 antibody was purified using Protein A affinity chromatography.
  • dissociation constants of the chimeric antibody cMAG-1 and the mouse antibody MAG-1 are essentially the same, while the dissociation constant for the humanized MAG (hMAG-1) is about 10 folds higher compared to cMAG-1 and MAG-1 (see Table 1).
  • Applicants compared the ability of the chimeric antibody cMAG-1 and the mouse antibody MAG-1 to inhibit the growth of estrogen-dependent MCF-7 and estrogen independent (triple negative) MDA-MB231 xenografts in nu/nu mice.
  • mice Three groups of nu/nu mice (8 mice for each group) were injected with 1 ⁇ 10 7 MCF-1 or MDA-MB231 tumor cells per mouse s.c. on the right flank, and the tumors were allowed to grow to an average of about 300 mm 3 in about 30 days.
  • MCF-7 cells prior to tumor cell injection, an estrogen pellet was inserted below the skin on the back just below the neck.
  • 50 ⁇ g of cMAG-1 or mMAG-1 antibody in PBS solution was injected intraperitoneally, once per day for 14 days.
  • the control group was injected similarly, but with xPBS.
  • Tumor volume was measured daily, and the relative average sizes of the tumors in each group, as compared to the volume at Day 0, were plotted against a time course of treatment in FIGS. 15 A & B.
  • FIG. 15A at treatment Day 10, the control group was injected with mMAG-1, as shown by the arrow.
  • FIGS. 15A & 15B The data shows that, in both instances, cMAG-1 was as efficacious as mouse MAG-1 in terms of inhibiting tumor growth or shrinking tumor size during treatment.
  • FIGS. 15A & 15B After 2 days of daily injections of cMAG-1 and mMAG-1, the size of the injected tumors shrank to about 60% of that of the original tumors on Day 0 (Day of commencing treatment), and tumor sizes remained stable for the remaining treatment period.
  • FIG. 15B further shows that, in the control group, after the average tumor size has reached about 150% of the original size at Day 10, a single injection of mMAG-1 dramatically reduced average tumor size to about the original size (100%).
  • MAG-1 was detected inside the cells incubated at 37° C., but not inside cells incubated at 4° C., indicating that the antibody-antigen complex was internalized.
  • Monoclonal antibody 520C9 FIG. 16B , which binds to the Herb2 receptor on the SKBr3 cells, was used as a positive control.
  • chimeric antibody cMAG-1 was also internalized after incubation with the SKBr3 cells for 24 hrs at 37° C.
  • MAG-1 enhances the efficacy of cyclophosphamide in combination therapy.
  • Example IX the animals were treated as in Example IX with about 100 ⁇ g of MAG-1 daily for 11 days, subsequent to treatment with about 50 mg/kg b.w. of cyclophosphamide daily for 3 days.
  • Three groups of nu/nu mice (8 animal per group) were injected with 1 ⁇ 10 ⁇ 7 recurrent H82 SCLC cells per mouse s.c. on the right flank, and the tumors were allowed to grow to an average of about 300 mm 3 in about 14 days. All treatment was carried out by injection intraperitoneally.
  • the control group animals were injected with PBS daily for 14 days, the cyclophosphamide group was injected with 50 mg/kg of cylcophosphamide per animal daily for 3 days, while the combined therapy group was treated with 50 mg/kg of cyclophosphamide per animals daily for 3 days and thereafter with 100 ⁇ g of MAG-1 per animal daily for another 11 days.
  • the data in FIG. 17 shows synergistic efficacy between MAG-1 and cyclophosphamide in treating SCLC xenografts.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Emergency Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Optics & Photonics (AREA)
US14/274,997 2011-11-11 2014-05-12 Provasopressin antagonists and uses thereof Abandoned US20140341802A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US14/274,997 US20140341802A1 (en) 2011-11-11 2014-05-12 Provasopressin antagonists and uses thereof
US15/289,260 US10155810B2 (en) 2011-11-11 2016-10-10 Provasopressin antagonists and uses thereof
US16/575,911 US20220242947A1 (en) 2011-11-11 2019-09-19 Provasopressin antagonists and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161558998P 2011-11-11 2011-11-11
PCT/US2012/064336 WO2013071030A1 (en) 2011-11-11 2012-11-09 Provasopressin antagonists and uses thereof
US14/274,997 US20140341802A1 (en) 2011-11-11 2014-05-12 Provasopressin antagonists and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/064336 Continuation WO2013071030A1 (en) 2011-11-11 2012-11-09 Provasopressin antagonists and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/289,260 Continuation US10155810B2 (en) 2011-11-11 2016-10-10 Provasopressin antagonists and uses thereof

Publications (1)

Publication Number Publication Date
US20140341802A1 true US20140341802A1 (en) 2014-11-20

Family

ID=48290579

Family Applications (3)

Application Number Title Priority Date Filing Date
US14/274,997 Abandoned US20140341802A1 (en) 2011-11-11 2014-05-12 Provasopressin antagonists and uses thereof
US15/289,260 Active US10155810B2 (en) 2011-11-11 2016-10-10 Provasopressin antagonists and uses thereof
US16/575,911 Abandoned US20220242947A1 (en) 2011-11-11 2019-09-19 Provasopressin antagonists and uses thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
US15/289,260 Active US10155810B2 (en) 2011-11-11 2016-10-10 Provasopressin antagonists and uses thereof
US16/575,911 Abandoned US20220242947A1 (en) 2011-11-11 2019-09-19 Provasopressin antagonists and uses thereof

Country Status (5)

Country Link
US (3) US20140341802A1 (de)
EP (1) EP2776064A4 (de)
AU (1) AU2012335610A1 (de)
CA (1) CA2854563A1 (de)
WO (1) WO2013071030A1 (de)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10155810B2 (en) 2011-11-11 2018-12-18 Woomera Therapeutics Provasopressin antagonists and uses thereof
US11129894B2 (en) * 2017-09-29 2021-09-28 - Humanetics Corporation Sensitizing cells to proton radiation
US11419827B2 (en) 2017-02-24 2022-08-23 Humanetics Corporation Protecting tissue and mitigating injury from radiation-induced ionizing events

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080267963A1 (en) * 2004-11-02 2008-10-30 Biomedical Research Model, Inc. Methods of Cancer Treatment/Prevention Using Cancer Cell-Specific Surface Antigens
WO2009137113A2 (en) * 2008-05-09 2009-11-12 Woomera Therapeutics, Inc. Peptides, antibodies, and uses thereof for identifying and targeting provasopressin-expressing cancer cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2015862A1 (en) * 1989-05-04 1990-11-04 Gajanan Nilaver Cell surface antigen that binds with l6 monoclonal antibody
ATE491727T1 (de) * 2002-07-16 2011-01-15 Woomera Therapeutics Inc Zusammensetzungen und deren verwendungen zur identifizierung und zum targetting von provasopressinexprimierenden krebszellen
EP1628136A1 (de) * 2004-08-19 2006-02-22 B.R.A.H.M.S. Aktiengesellschaft Diagnoseverfahren für Krankheiten unter Verwendung von Copeptin
DE102006053442A1 (de) * 2006-11-12 2008-05-15 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung von Infektionen und chronischen Erkrankungen der Atemwege und Lunge mittels proVasopressin, insbesondere Copeptin oder Neurophysin II
EP2776064A4 (de) 2011-11-11 2015-08-05 Woomera Therapeutics Provasopressin-antagonisten und ihre verwendungen

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080267963A1 (en) * 2004-11-02 2008-10-30 Biomedical Research Model, Inc. Methods of Cancer Treatment/Prevention Using Cancer Cell-Specific Surface Antigens
WO2009137113A2 (en) * 2008-05-09 2009-11-12 Woomera Therapeutics, Inc. Peptides, antibodies, and uses thereof for identifying and targeting provasopressin-expressing cancer cells

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Biete et al (Reports of Practical Oncology and Radiotherapy, March/April 2010, 15:27-30) *
North (Experimental Physiology, 2000, 85S:27S-40S) *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10155810B2 (en) 2011-11-11 2018-12-18 Woomera Therapeutics Provasopressin antagonists and uses thereof
US11419827B2 (en) 2017-02-24 2022-08-23 Humanetics Corporation Protecting tissue and mitigating injury from radiation-induced ionizing events
US11129894B2 (en) * 2017-09-29 2021-09-28 - Humanetics Corporation Sensitizing cells to proton radiation
US11779644B2 (en) 2017-09-29 2023-10-10 Humanetics Corporation Sensitizing cells to proton radiation

Also Published As

Publication number Publication date
US20220242947A1 (en) 2022-08-04
CA2854563A1 (en) 2013-05-16
EP2776064A1 (de) 2014-09-17
US20170107283A1 (en) 2017-04-20
AU2012335610A1 (en) 2014-06-12
US10155810B2 (en) 2018-12-18
EP2776064A4 (de) 2015-08-05
WO2013071030A1 (en) 2013-05-16

Similar Documents

Publication Publication Date Title
US7420041B2 (en) Cytotoxicity mediation of cells evidencing surface expression of TROP-2
JP7063623B2 (ja) 治療用抗体およびその使用
US20220242947A1 (en) Provasopressin antagonists and uses thereof
US20160257756A1 (en) Antibodies against ccr9 and applications thereof
CN101687930A (zh) 介导癌细胞细胞毒性的嵌合和人源化抗cd44抗体
AU2007218959A1 (en) Cancerous disease modifying antibodies
AU2008255526A1 (en) Humanized and chimeric anti-CD59 antibodies that mediate cancer cell cytotoxicity
EP1539818B1 (de) Zusammensetzungen und deren verwendungen zur identifizierung und zum targetting von provasopressinexprimierenden krebszellen
AU2003251966A2 (en) Compositions and uses thereof for identifying and targeting provasopressin-expressing cancer cells
US10407504B2 (en) Antagonists for abdominal vasopressin V2 receptor and uses thereof
CN105828841A (zh) 抗-efna4抗体-药物缀合物
WO2009137113A2 (en) Peptides, antibodies, and uses thereof for identifying and targeting provasopressin-expressing cancer cells
US7485300B2 (en) Cancerous disease modifying antibodies
TW200936757A (en) Cancerous disease modifying antibodies
JP2011528010A (ja) 癌性疾患修飾抗体
JP2011511767A (ja) 細胞傷害性抗癌モノクローナル抗体
WO2008058380A1 (en) Cancerous disease modifying antibodies
JP2011520923A (ja) 細胞傷害性抗癌モノクローナル抗体

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION